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Introduction: 
 
Global Situation 
Despite substantial progress in hygiene and sanitation and a significant reduction of typhoid fever and 
cholera in most developed countries, both diseases remain of immanent importance and a permanent 
threat in many developing countries. 
Crump et al (2004) reviewed 22 studies on burden of disease of typhoid fever published in peer reviewed 
journals from around the globe and conclude that more than 21.000.000 episodes of typhoid fever 
occurred in the year 2000 (see fig. 1), with more than 215.000 deaths. The same study highlights the 
differences in burden of disease between developing and developed countries, categorizing Europe, 
North America, Australia, and New Zealand as areas with <10 episodes of typhoid fever per 100.000 
population, whereas south- central and south – east Asia where considered as high endemic (>100 / 
100.000) and the rest of the world as medium incidence (10-100 / 100.000) (Crump et al, 2004). More 
recent publications suggest that these numbers may be an underestimate for Africa. Thriemer et al. 
(2012) report incidence rates as high as 110/ 100.000 population from Zanzibar, Tanzania; Breiman et al 
(2012) observed crude incidence rates of 247 / 100.000 person years of observation in an urban slum in 
Kenya (Breiman et al, 2012).  
 
Fig. 1: Geographical distribution of typhoid fever, 2000 
 
From: Crump, J. A., S.P. Luby, E. D. Mintz. (2004): The global burden of typhoid fever. Bulletin of the World Health Organization 
82 (5):346—353. 
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Similar to typhoid fever, cholera is endemic in developing countries only (see fig. 2). While neither 
Europe, the Northern Americas, Australia, or New Zealand report non-imported, local cholera cases, the 
main burden of disease lies within Africa, the Indian subcontinent and Haiti. David Sack (2012) estimated 
2.55 mio. cases globally / year with a case fatality rate of >8.2%. He concludes that case fatality rates are 
almost threefold higher in Africa (11.9%), compared to Asia (4.1%).  
 
Fig.2: Areas reporting Cholera outbreaks2010-2011to the WHO 
 
From: World Health Organization (2012): Cholera, areas reporting outbreaks, 2010-2011 [online]: 
http://gamapserver.who.int/mapLibrary/Files/Maps/Global_Cholera_ITHRisk_20120118.png (last accessed on 19.03.2012) 
 
Favoring circumstances and possible interventions 
Typhoid fever and cholera are transmitted via fecal-oral infection (WHO, 2009a; WHO 2010) and are 
poverty associated diseases (Miller et al, 2000; Zuckerman et al, 2007). Informal settlements, refugee 
camps, and disaster zones are prone to outbreaks of either disease, due to the lack of access to safe and 
clean water and a functioning sewage system. The cholera outbreaks in 2011 / 2012 in Haiti have 
dramatically shown how the destruction of local infrastructure may result in an outbreak situation; 
studies conducted in the years 2007 – 2009 in Kibera, Kenya (Breiman et al, 2012), one of Africas biggest 
slums, demonstrate the permanent danger of a typhoid fever infection for people with limited access to 
drinking and no sewage water system. 
 
While improving local infrastructure is a sustainable long term solution, this is often not possible due to 
budget limitations in developing countries or the character of a sudden disaster. Since both diseases, 
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typhoid fever and cholera, are preventable through vaccination (Lesser and Miller in Kasper et al, 2005a; 
Waldor and Keusch in Kasper et al, 2005b) reactive vaccination campaigns may be considered effective in 
case of an outbreak as has been shown through modeling for cholera (Reyburn et al, 2011). Since both 
diseases are curable (Ghenghesh et al, 2009; WHO, 2009a) by standard antibiotics (typhoid fever) and 
rehydration (cholera) if detected soon after onset of symptoms (Lesser and Miller in Kasper et al, 2005a; 
Waldor and Keusch in Kasper et al, 2005b; WHO, 2009b; WHO 2010; Baker et al, 2010), an early and 
precise diagnosis of disease is essential. Precise and accurate diagnosis will support planning of 
preventive and reactive measures by providing reliable data on disease burden and trends.  
 
Funding Dilemma 
Many areas suffering from high incidence rates of typhoid fever and cholera are facing the dilemma that 
both diseases have a negative impact on the affected populations’ macro-economic situation, resulting 
in insufficient funding for diagnostic facilities and staff. Insufficient funding for diagnosis and treatment 
in return results in high disease incidence rates, prolonged episodes of disease and high case fatality 
rates (CFR) due to treatment errors. These factors result in a negative impact on the macro-economy of 
the affected society (Aguayo-Rico et al, 2005), resulting in low GDP and in turn poor funding for health 
systems. 
 
One possible solution to this diagnostic dilemma is treatment and reporting based on clinical picture 
only. However as the clinical picture especially for typhoid fever is subject to a broad variety of 
symptoms (Lesser and Miller in Kasper et al, 2005a; Thriemer et al, in preparation) empirical treatment 
based exclusively on the clinical picture is often insufficient, may lead to treatment errors and thereby 
increases cost of illness.  
Since cholera as any episode of acute watery diarrhea is mainly treated symptomatically through fluid 
replacement (Waldor and Keusch in Kasper et al, 2005b), an accurate and immediate diagnosis is not 
essential. However, since the route of infection for both diseases is fecal – oral, appropriate and early 
diagnosis is likely to reduce or inhibit spreading of disease and will support early identification of 
outbreaks and on-setting epidemics. The impact on public health is therefore significant. 
 
Laboratory Confirmation 
In both cases confirmation of disease requires a well equipped laboratory, knowledge on laboratory 
procedures and sufficient funding for equipment and consumables. While the gold standard for diagnosis 
of typhoid fever is automated blood culture and agglutination testing, confirmation of Vibrio cholerae is 
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performed by stool culture and agglutination testing (Cheesborough, 2006a; Cheesborough 2006b; 
Perilla et al, 2003). 
Automated blood culture requires a blood culture machine, an incubator as well as further standard 
laboratory equipment such as a fridge / freezer for storage of consumables, a safety cabinet for sample 
handling and access to distilled water for media preparation. The process of pathogen isolation and 
identification requires a number of selective and differential media as well as antisera and may take up 
to seven days. Excluding running costs such as electricity, labor costs, and purchase of machinery, we 
found that processing a single sample for blood culture cost approximately 20-30 US Dollars (USD) in our 
study setting. 
Stool culture for Vibrio cholerae requires less machinery, apart from an incubator and a fridge for storage 
as well as access to distilled water and can be completed within 24 – 48 hours. If laboratory procedures 
are reduced to a minimum, including only selective media, enrichment media and gelatine agar for later 
agglutination testing as well as antisera, processing one stool sample cost approximately 4 USD in the 
below described study. 
 
Aim of this Thesis 
Considering that many of the above addressed issues can’t be provided in a sustainable manner in a 
number of developing country settings this thesis addresses the problem of accurate diagnosis by 
evaluating three different rapid diagnostic tests (RDTs)under developing country conditions. The 
outcome of this thesis may provide a basis for decision makers to include / exclude the assessed RDTs for 
the future in the diagnostic process.   
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Background 
 
Rapid Diagnostic Tests  
Any rapid diagnostic test should fulfill the following requirements if introduced in public health systems: 
 
• High reliability 
• High accuracy 
• Convenient and simple operational characteristics 
• Cost effectiveness 
• Good availability 
 
Widal Test 
A number of rapid diagnostic tests exist and are available for typhoid fever (Olopoenia & King, 2000). The 
Widal test, possibly the first rapid diagnostic test developed was first introduced in 1896 by F. Widal 
(Olopoenia & King, 2000). The test is based on a macroscopically visible agglutination reaction between 
anti - Salmonella Typhi specific antibodies of patient’s serum and somatic S. Typhi O and flagellar H 
antigens in a solution (Olopoenia & King, 2000).  
Agglutination may be performed on a slide, whereby patient serum is separately mixed with O or H 
antigen and observed for macroscopically visible agglutination. Of better diagnostic value is the tube 
agglutination approach, whereby patient serum is diluted in doubling steps, mixed with the respective 
antigen, incubated in a water bath and then observed for agglutination (Olopoenia & King, 2000). Albeit 
this approach is more labor intensive specificity is better than with the slide agglutination test 
(Olopoenia & King, 2000).  One of the major obstacles with the Widal test is its poor performance due to 
cross reactivity and the requirement to establish local cut off titers, which will have to be re-evaluated in 
regular time intervals and can’t be transferred to other settings. Despite its shortcomings the test is 
widely in use in Sub-Saharan Africa (Olopoenia & King, 2000; Mweu & English, 2008) due to its very 
competitive price of less than 50 US cents / test. 
 
Tubex Test 
A number of other test kits have been developed over the last twenty years that do not require a local 
cut off titer, though at a higher price, one of them being the TUBEX (IDL, Sweden). The mode of action 
for all of these tests may be considered as a variation of the Widal test with techniques adapted from an 
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Enzyme Linked Immuno Sorbent Assay (ELISA) (Kawano et al, 2007). The test is based on an inhibition 
reaction between patient antibodies (pAB) and monoclonal antibodies (mAB): 
Magnetic beads coated with antigen (Ag) are added to patient serum in a reaction well. If the patient 
serum contains pAB these will bind to the magnetic beads and will inhibit binding of blue colored beads 
coated with mAB. If placed on a magnet, the magnetic beads will sink to the bottom of the reaction well, 
while the blue beads will remain in solution, coloring the solution blue. If no pAB are present, mAB beads 
will bind to Ag beads, both will sink to the wells bottom and the solution will decolorize.  
The blue intensity of the final solution can be compared to a provided color scale, in order to grade the 
obtained result on a scale from 1-10, whereby any result >3 should be considered positive according to 
manufacturer. 
 
Figure 3: Mechanism of the Tubex Test. 
  
 
 
 
 
 
 
 
 
 
Lim et al, One-Step 2-Minute Test To Detect Typhoid-Specific Antibodies Based on Particle Separation in Tubes, JOURNAL OF 
CLINICAL MICROBIOLOGY, Vol. 36 (8) Aug. 1998, p. 2271–2278 
 
The test has three major advantages over the Widal test: 
1. The test measures only immunoglobulin M (IgM) and hence only recent infections (Tam and Lim, 
2003) 
2. The used Ag (O9) is highly specific, cross reactions are less than for the Widal (Lim et al, 1998) 
3. The test has a universally applicable cut – off titre. 
 
However the test is significantly more expensive than the Widal test at approximately 2.15 USD / test 
and does not work on hemolyzed serum samples with the standard procedures described above. 
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Crystal VC 
 
In 2003 the Institute Pasteur developed a dipstick rapid diagnostic test for cholera. Through licensure 
agreement the test was made available to the Indian company Span Diagnostics and is currently 
produced and distributed through said company under the name Crystal VC.  
The test uses immunochromatographic methods, and detects Ag of V. cholerae O1 and O139 (Kalluri et 
al, 2006). In detail the test strip is inserted into (liquid) stool. A pad on the test strip contains mobile mAB 
conjugated to gold nanoparticles. Through capillary forces the sample is dragged across the mobile mAB, 
which bind to any Ag present in the stool. When passing over a test line with stationary mAB this second 
set of mAB binds to a different epitope of the same Ag, immobilizing the Ag-mAB complex. The 
conjugated gold nanoparticles appear as a positive test line. Further upstream is a third set of mAB, 
which bind to the mobile mAB, whereby a test line appears, and confirms correct test procedures. This 
design (with slight variations) is used for a number of rapid diagnostic tests including pregnancy (urine) 
and malaria (blood) tests and is considered to be easy in use and handling.  
After development by the Institute Pasteur a prototype of the current test was evaluated in 2003 by 
Nato et al. in Madagascar, successive evaluation studies of the prototype followed (Bhuiyan et al, 2003, 
Wang et al, 2006, Kalluri et al, 2006). First evaluation studies of the commercial version where 
performed in 2009 in Guinea Bissau (Harris et al) and 2010 India (Mukherjee et al), however with varying 
test strips and procedures and small sample sizes of <220 samples. While sensitivity remained >90% in all 
studies, a decrease in specificities had been observed after Span Diagnostics took up production and it 
had been suggested that test performance may be influenced by reader qualification and experience 
(Kalluri et al, 2006).           
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Performance Indicators 
The performance of a diagnostic test can be assessed using a set of standardized indicators (Bruce et al, 
2008): 
• Sensitivity describes the percentage of correctly identified true positive (TP) samples from all 
true positives as well as false negative (FN) samples. (TP/TP+FN)  
• Specificity describes the number of correctly identified true negative samples (TN) among all 
samples that are truly negative. (TN/TN+FP) 
• The positive predictive value (PPV) describes the likelihood that an individual with a positive test 
result has the disease (TP/TP+FP) 
• The negative predictive value (NPV) indicates the likelihood in percent, that the test correctly 
excludes a respective diagnosis (TN/TN+FN) 
Sensitivity and specificity are retrospective (Altmann and Bland, 1994a) indicators and hence of 
importance for surveillance while not being applicable for routine diagnosis. Sensitivity and specificity 
describe the likelihood that a disease positive individual will achieve a positive result (sensitivity) or that 
a disease negative individual will be tested negative (specificity). Both indicators are independent of 
disease prevalence within the study population and hence provide the basis for test comparison in 
between different settings (Altmann and Bland, 1994a, Loong, 2003). 
PPV and NPV on the other hand are often considered the most important indicators for the practical 
application of a test. These indicators describe the likelihood that if a test result is obtained this result 
describes the true presence or absence of disease within the test subject. However both indicators are 
dependent on prevalence of disease (Altmann and Bland, 1994b, Loong, 2003). While PPV will improve 
with disease prevalence, since the number of FP become a smaller fraction in the presence of high 
numbers of TP, whereas the NPV will decrease since the fraction of TN among all negative test results is 
less, whereas this is not the case for FN results. In the presence of low prevalence on the other hand, 
PPV decreases, while NPV improves. 
Both indicators may therefore also be calculated as a function of sensitivity, specificity, and prevalence 
(Altmann and Bland, 1994b): 
 
• PPV = (sensitivity*prevalence) / (sensitivity*prevalence+(1-specificity)*(1-prevalence))   
• NPV = (specificity*(1-prevalence))/((1-sensitivity)*prevalence)+specificity*(1-prevalence)) 
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Gold Standard and control groups 
In order to evaluate a rapid diagnostic test a method needs to be defined that confirms or contradicts 
the rapid test result and is considered as 100% correct. This assumption in itself introduces a bias, the 
sensitivity of the gold standard will later need to be taken into consideration for analysis. A gold standard 
hence needs to be a widely accepted method, which is considered superior to other methods and 
follows a standardized protocol.  
For the purpose of the below described studies, automated blood culture was considered as the gold 
standard for typhoid fever. Using blood culture as a gold standard poses the problem of defining 
adequate control groups against which the performance indicators can be measured. Blood culture will 
in the case of typhoid fever identify three categories of samples: Salmonella Typhi positives samples, 
samples with another human pathogenic bacterial blood stream infection and samples with no positive 
test result. Since blood culture has a sensitivity of 40-80% (Bhutta, 2006; Farooqui et al; 1991; Gilman et 
al; 1975; Wain et al, 2001; Parry et al, 2002; Wilke et al, 2002), the last category is likely to consist of TN 
as well as FN results which will affect performance calculations. To address this problem different control 
groups have been defined for below projects, namely all blood culture negative results as well as all 
cases where a human pathogenic bacterial infection had been isolated. Since samples were collected in 
the course of a fever study at local hospitals we assumed that it is unlikely that if a likely bacterial cause 
for the febrile episode could be identified, the participant in addition suffered from an unrecognized S. 
Typhi infection. 
Since stool culture was chosen as the gold standard for the diagnosis of cholera, it was not possible to 
define control groups in a similar manner since all samples are streaked out on highly selective media 
(TCBS) initially (Murray et al, 2007). It was hence not possible to define comparable categories, since 
TCBS inhibits most other growth apart from Vibrio spp. (Murray et al, 2007). In contrast to collected 
blood samples, stool samples for this study where selected in the course of a cholera surveillance 
project, inclusion criteria were defined to exclude as many other possible diarrheal pathogens. 
Categories applied here therefore were growth or no growth. To reduce the number of FN enrichment 
media was used prior to plating.  
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Results: 
 
Results of the performance assessment for Widal, Tubex, and Crystal VC are presented in the below 
manuscripts. All manuscripts have been published in international peer reviewed journals. 
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Abstract 
 
Background: The diagnosis of typhoid fever is confirmed by culture of Salmonella enterica serotype Typhi 
(S. typhi). However, a more rapid, simpler, and cheaper diagnostic method would be very useful 
especially in developing countries.  The Widal test is widely used in Africa but little information exists 
about its reliability. 
Methods: We assessed the performance of the Widal tube agglutination test among febrile hospitalized 
Tanzanian children. We calculated the sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV) of various anti-TH and –TO titers using culture-confirmed typhoid fever 
cases as the “true positives” and all other febrile children with blood culture negative for S. typhi as the 
“true negatives.” 
Results: We found that 16 (1%) of 1,680 children had culture-proven typhoid fever. A single anti-TH titer 
of 1:80 and higher was the optimal indicator of typhoid fever. This had a sensitivity of 75%, specificity of 
98%, NPV of 100%, but PPV was only 26%. We compared our main findings with those from previous 
studies. 
Conclusion: Among febrile hospitalized Tanzanian children with a low prevalence of typhoid fever, a 
Widal titer of ≥ 1:80 performed well in terms of sensitivity, specificity, and NPV. However a test with 
improved PPV that is similarly easy to apply and cost-efficient is desirable. 
 
Background 
 
Salmonella enterica serotype Typhi (S. typhi), the causative agent of typhoid fever, was calculated to 
have caused approximately 200,000 deaths globally in 2000 [1]. The clinical picture of typhoid fever is 
nonspecific; confirmed diagnosis through blood or bone-marrow culture requires expensive and labor-
intensive isolation and identification of the organism, which may take up to seven days. A cheap and 
rapid alternative laboratory test is desirable, especially for developing country settings where typhoid 
fever is a major public health burden. 
 
Various agglutination tests have been developed [2] of which the Widal method is the oldest and 
remains the most widely used. The test was first introduced by F. Widal in 1896 [2] and is based on a 
macroscopically visible serum – mediated agglutination reaction between S. typhi somatic 
lipopolysacharide O antigens (TO) and flagellar H antigens (TH). Laboratories in industrialized countries 
have stopped performing the assay. In Africa the Widal test is still widely used [3] because typhoid fever 
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is perceived to be endemic in the area [3] and the Widal test is the only rapid diagnostic assay that is 
available and affordable. The Widal test is commonly performed when children and adults present with 
fever to treatment centers, as few centers have the capacity to perform micro-bacterial  culture [4]. 
Despite this widespread use, little has been published on its performance in Africa.  
We assessed the sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) of the Widal tube agglutination test among Tanzanian children hospitalized with  febrile illness  
and compared our results with those from previous studies. 
 
Methods 
 
Study site and population. The study was conducted as part of a childhood fever surveillance study at 
Teule Hospital in Muheza district of Northeastern Tanzania from 2008 to 2009. Muheza district is located 
between the foothills of Kilimanjaro and the coastal town of Tanga. The area is highly endemic for 
Plasmodium falciparum malaria with perennial transmission and two seasonal peaks [5]. HIV sero-
prevalence among antenatal clinic attendees was about 7% in 2007 [6]. Teule Hospital is a busy 330-bed 
district-level general hospital, serving a surrounding population of 277,000. It has two 35-bed in-patient 
pediatric wards receiving approximately 5,000 child admissions per year (2008). 
 
Inclusion Criteria: Children aged 2 months to 14 years were screened for eligibility during study hours 
from 7am to 7pm, Monday to Sunday. Children with fever of 3 or more days prior to admission, or fever 
of less than 3 days but with at least one severity criteria (respiratory distress, deep breathing, respiratory 
distress in combination with severe pallor, prostration, capillary refill ≥ 3 seconds, temperature gradient, 
systolic blood pressure < 70 mm Hg,  coma defined by Glasgow Coma Scale ≤ 10 or Blantyre Coma Scale ≤ 
2, severe jaundice, history of 2 or more convulsions in the last 24 hours, blood glucose < 3 mmol 
associated with clinical signs, neck stiffness, bulging fontanel, or oxygen saturation < 90%) were recruited 
into the study. All clinical information was recorded on a standard case record form. Treatment was 
provided according to national guidelines. On admission we collected 3 to 5 milliliters (ml) of blood 
(depending on body weight) from each eligible child for the Widal test and a single blood culture. All 
clinical procedures were performed by trained study clinical officers and nurses under the supervision of 
study physicians. 
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Laboratory. Blood for culture was inoculated into BacT/ALERT™ Pediatric-fan bottles (bioMérieux, Marcy 
l’Etoile, France). Inoculated blood culture bottles were transported immediately to the hospital 
laboratory and incubated in the BacT/ALERT 3D automated microbial detection system. Blood cultures 
were processed according to standard methods. Colonies with biochemical reactions on API20E 
suggestive of Salmonellae were confirmed serologically by slide and tube agglutination testing using 
specific O and H antisera (Becton Dickinson, NJ, USA).  
 
A minimum of 0.5 ml of blood was separated to obtain serum samples. All serum samples were frozen at 
-70°C until Widal testing was done in three batches. Widal testing was performed using standardized TO 
(IgM and IgG) and TH (IgG) antigens (Stained Salmonella Antigens kit, Span Diagnostics, India) according 
to standard methods as described on the package insert. In brief, each sample was diluted to a 
concentration of 1:40 with 0.9% NaCl in two separate plastic tubes. A single drop of antigen was added 
to the respective tube. Incubation times for both O and H agglutinations were 16 to 20 hours at 37°C in a 
water bath. Evaluation of test results was performed by at least two lab technicians on an independent 
basis under standardized light conditions. If agglutination was detected in a sample, testing was done on 
that sample diluted serially from 1:80 to 1:1280 for both O and H antigens. All laboratory procedures 
were performed by trained laboratory technicians under the supervision of microbiologists. Technicians 
performing the Widal tests were blinded to the participants’ clinical picture and blood culture results. 
 
Data management. Case report forms were double-entered into custom-made data entry programs 
using MS-Access (Microsoft Corp.). Data management programs included error, range, and consistency 
check programs. Analyses were performed using EpiInfo v 3.4.3 (Centers for Disease Control and 
Prevention, USA) and Stata TM v 10.0 (Stata Corp., USA).   
 
Definitions and analysis. Fever was defined as stated history or presence of fever of ≥37.5°C. Bacteremia 
was defined as fever with isolation of pathogenic bacteria from blood culture. Children with a febrile 
illness were classified as follows: those with S. typhi subsequently isolated from blood culture (group 1), 
those with non-Typhi serotypes of S. enterica (NTS) subsequently isolated from blood culture (group 2), 
those with pathogenic bacteria other than Salmonellae subsequently isolated from blood culture (group 
3), and those whose blood culture yielded no bacterial pathogen (group 4).  Malaria status was not 
considered in the classification. In areas of high transmission of P. falciparum where individuals develop 
immunity from previous episodes of malaria starting at a young age, asymptomatic parasitemia is 
common and may be detected during febrile episodes caused by another infection [7,8].  
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For the primary analysis, sensitivity (true-positive rate) was defined as the probability that the Widal test 
result would be positive when blood culture confirmed that typhoid fever was present (group 1) and 
specificity (true-negative rate) was the probability that the Widal test result would be negative when S. 
typhi was not isolated from blood culture (groups 2, 3, and 4). The positive predictive value was the 
probability that culture-confirmed typhoid was present when the test was positive, and the negative 
predictive value was the probability that culture-confirmed typhoid was not present when the test was 
negative. Since serological tests detect antibody response and perform better after a period of time from 
the onset of the illness, sensitivity, specificity, PPV, and NPV were also calculated separately for cases 
presenting with fever for 5 days or less and for more than 5 days. Because controversy exists about what 
is the most appropriate control group to use [9,10,11], we conducted a secondary analysis using two 
alternative “true-negative” control groups as follows: those with NTS and other pathogenic bacteria 
isolated from blood culture (groups 2 and 3), and those with pathogenic bacteria other than Salmonellae 
isolated from blood culture (group 3). 
 
Comparisons were made using the Chi square or Fishers’ Exact test, as appropriate. Sensitivity, 
specificity, PPV, and NPV were calculated according to standard methods. The 95% confidence interval 
for sensitivity and specificity was calculated using the Wilson’s Score method [12]. Analyses were 
performed using EpiInfo v 3.4.3 (Centers for Disease Control and Prevention, USA) and Stata TM v 10.0 
(Stata Corp., USA).  
 
Literature review. We conducted a literature review to compare our main findings with those from 
previous studies of similar character. We included studies of the Widal test which were identified by 
direct searches of the MEDLINE database through PubMed. The searches were restricted to publications 
from 1993 to date. We also conducted supplementary searches of the references in retrieved articles. 
Abstracts were reviewed and if relevant, the article was included. 
 
Ethics. The fever surveillance was conducted following the principles governing biomedical research 
involving human subjects. Prior written informed consent was obtained from the parent or guardian of 
all study participants. The study protocol was approved by the National Institute of Medical Research, 
Tanzania, and the International Vaccine Institute Institutional Review Board.  
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Results 
The flow of patients is shown in Figure 1. A total of 1,706 febrile children were enrolled out of which 26 
(1.5%) were excluded for the following reasons: 19 or 1.1% had no blood culture done, 6 or 0.4% had no 
Widal testing done due to insufficient quantities of sera, and one case or 0.1% had no blood culture nor 
Widal testing done. A total of 1,680 (98.5%) samples were included in the analysis. There were 16 or 
1.0% culture-confirmed typhoid fever cases (group 1), 49 or 2.9% with NTS infection (group 2), and 113 
or 6.7% with non-Salmonella bacteremia (group 3). From 1,502 (89.4%) children, no pathogenic bacteria 
were isolated from blood culture (group 4). 
 
FIGURE 1. Flow of patients 
 
 
* Species included: Streptococcus pneumonia (n=11), beta hemolytic Streptococci (n=10), Staphylococcus aureus (n=5), 
Haemophilus influenzae type b (n=26), Escherichia coli (n=31), Acinetobacter species (n=6), Non-fermenters (n=12),  Others: 
(n=5), Haemophilus parainfluenzae (n=2), and Gram negative rods not identified (n=5).  
** Species included: Bacillus (n=22), Diphtheroids (n=7), Micrococcus (n=9), alpha-hemolytic Streptococcus viridans (n=4), 
coagulase negative Staphylococcus (n=104), yeast (n=5), mixed bacterial species (n=4), Gram positive rods not identified (n=1). 
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We assessed the age distribution and highest anti-TH and -TO titer by blood culture-confirmed diagnosis 
(Table 1). Children with typhoid fever were significantly older compared to the other groups. Anti-TH 
agglutination titers of 1:80 and higher were detected among 12/16 (75.0%) culture-confirmed typhoid 
fever cases compared to 7/49 (14.3%) of those with NTS infection, and 1/113 (0.9%) with other 
bacteremia (p values = 0.001 and <0.001, respectively). Similarly, anti-TO agglutination titers of 1:80 and 
higher were detected among 11/16 (68.8%) cases of typhoid fever compared to 7/49 (14.3%) of those 
with NTS infection and 0/113 (0%) with other bacteremia (p values <0.001 and <0.001, respectively).  
 
TABLE 1. Number and cumulative frequencies of anti-TH and anti-TO levels overall and by blood culture 
isolates 
* P values: Group 1 vs 4 <0.001; Group 2 vs 4 = 0.209; Group 3 vs 4 = 0.013 
 
 
Primary analysis. We calculated the sensitivity, specificity, PPV, and NPV of various Widal test cut-offs 
for the diagnosis of typhoid fever (Table 2). The sensitivity, specificity, PPV, and NPV of an anti-TH titer of 
1:80 were 75, 98, 26, and 100%, respectively. The sensitivity, specificity, PPV, and NPV of an anti-TO titer 
of 1:80 were 69, 98, 25, and 100%, respectively.    
 
 
 
 
 
Highest titer 
reached; 
Number (%) 
 
All 
(n=1,680) 
Children with 
culture-
confirmed 
typhoid fever 
(n=16) 
Children with 
non-Typhi 
serotypes of S. 
enterica (n=49) 
Children with 
other 
pathogenic 
bacteria 
(n=113) 
Children with 
no pathogenic 
bacteria 
isolated 
(n=1,502) 
Median age 
(Range)* 
1.83 
(14.81) 
7.21  
(11.96) 
1.58 
(6.73) 
1.43 
(11.83) 
1.84 
(14.81) 
Anti-TH      
≥1:640  15 (0.9) 3 (18.8) 5 (10.2) 0 (0) 7 (0.5) 
1:320 24 (1.4) 6 (37.5) 6 (12.2) 0 (0) 12 (0.8) 
1:160 36 (2.1) 11 (68.8) 7 (14.3) 0 (0) 18 (1.2) 
1:80 46 (2.7) 12 (75.0) 7 (14.3) 1 (0.9) 26 (1.7) 
1:40 85 (5.1) 12 (75.0) 9 (18.4) 3 (2.7) 61 (4.1) 
No agglutination 1,595 (94.9) 4 (25.0) 40 (81.6) 110 (97.3) 1,441 (95.9) 
Anti-TO      
≥1:640  6 (0.4) 3 (18.8) 2 (4.1) 0 (0) 1 (0.1) 
1:320 18 (1.1) 6 (37.5) 3 (6.1) 0 (0) 9 (0.6) 
1:160 34 (2.0) 10 (62.5) 6 (12.2) 0 (0) 18 (1.2) 
1:80 44 (2.6) 11 (68.8) 7 (14.3) 0 (0) 26 (1.7) 
1:40 95 (5.7) 12 (75.0) 10 (20.4) 3 (2.7) 70 (4.7) 
No agglutination 1,585 (94.3) 4 (25.0) 39 (79.6) 110 (97.3) 1,432 (95.3) 
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TABLE 2. Primary analysis for the performance* of the Widal test for typhoid fever diagnosis (n=1680) 
*The values were calculated using culture-confirmed typhoid fever cases (group 1; n=16) as the true positives and those cases 
from which S. typhi were not isolated from blood culture (groups 2, 3, and 4; n=1664) as the true negatives.  
 
 
We compared the performance of the Widal test between patients who presented with fever of 5 days 
or less and those who presented with more than 5 days of fever (Table 3). Of the 16 typhoid fever cases, 
6 (37.5%) presented with fever of 5 days or less, and 10 (62.5%) with more than 5 days of fever. Of the 
1,664 children in the control group, 1,117 (67%) presented with fever of 5 days or less and 544 (33%) 
with more than 5 days of fever. Three control cases, whose fever duration was unknown, were excluded 
from the analysis. The sensitivity of an anti-TH and -TO titer of 1:80 increased, however not significantly, 
from 67% to 80% and 67% to 70%, respectively, with the longer duration of fever prior to admission 
(both p>0.05). The PPV of an anti-TH and -TO titer of 1:80 increased from 21% to 30% and 19% to 30% 
(both p>0.05), respectively, with the longer duration of fever prior to admission. But the change was also 
not statistically significant.   
 
 
 
 
 
 
 
 
 
Widal titer
  
Sensitivity 
(95%CI) 
Specificity (95%CI) Positive Predictive 
Value 
Negative Predictive 
Value 
TH ≥1:80 12/16, 0.75 (0.51-
0.90) 
1630/1664, 0.98 
(0.97-0.99) 
12/46, 0.26 1630/1634, 1.00 
TH ≥1:160 11/16, 0.69 (0.44-
0.86) 
1639/1664, 0.98 
(0.98-0.99) 
11/36, 0.31 1639/1644, 1.00 
TH ≥1:320 6/16, 0.38  
(0.18-0.61) 
1646/1664, 0.99 
(0.98-0.99) 
6/24, 0.25 1646/1656, 0.99 
TO ≥1:80 11/16, 0.69 (0.44-
0.86) 
1631/1664, 0.98 
(0.97-0.99) 
11/44, 0.25 1631/1636, 1.00 
TO ≥1:160 10/16, 0.63 (0.39-
0.82) 
1640/1664, 0.99 
(0.98-0.99) 
10/34, 0.29 1640/1646, 1.00 
TO ≥1:320 6/16, 0.38  
(0.18-0.61) 
1652/1664, 0.99 
(0.99-1.00) 
6/18, 0.33 1652/1662, 0.99 
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TABLE 3. Comparison of the performance* of the Widal test for typhoid fever diagnosis by number of 
days of fever** prior to admission  
 
 *The values were calculated using culture-confirmed typhoid fever cases (group 1; n=16) as the true positives and those cases 
from which S. typhi were not isolated from blood culture (groups 2, 3, and 4; n=1664) as the true negatives.  
** Three patients whose fever duration was unknown were excluded from the analysis. 
 
 
Secondary analysis. Using different control groups, we compared the resulting sensitivity, specificity, 
PPV, and NPV of a Widal test cut-off of an anti-TH and -TO titer of ≥1:80 for the diagnosis of typhoid 
fever (Table 4). Changing the control group had no significant effect on the sensitivity, specificity, and 
NPV but markedly increased the PPV of an anti-TH titer of ≥1:80 from 26% to 92% and the PPV of an anti-
TO titer of ≥1:80 from 25% to 100%. 
 
 
Widal 
titer 
Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
Positive Predictive 
Value 
Negative Predictive 
Value 
≤ 5 days fever (n=1123)    
TH ≥1:80 4/6, 0.67 
(0.30-0.90) 
1102/1117, 0.99 
(0.98-0.99) 
4/19, 0.21 1102/1104, 1.00 
TH ≥1:160 3/6, 0.50 
(0.19-0.81) 
1106/1117, 0.99 
(0.98-0.99) 
3/14, 0.21 1106/1109, 1.00 
TH ≥1:320 2/6, 0.33 
(0.10-0.70) 
1110/1117, 0.99 
(0.99-1.00) 
2/9, 0.22 1110/1114, 1.00 
TO ≥1:80 4/6, 0.67 
(0.30-0.90) 
1100/1117, 0.98 
(0.98-0.99) 
4/21, 0.19 1100/1102, 1.00 
TO ≥1:160 3/6, 0.50 
(0.19-0.81) 
1107/1117, 0.99 
(0.98-1.00) 
3/13, 0.23 1107/1110, 1.00 
TO ≥1:320 1/6, 0.17 
(0.03-0.56) 
1112/1117, 1.00 
(0.99-1.00) 
1/6, 0.17 1112/1117, 1.00 
> 5 days fever (n=554)      
TH ≥1:80 8/10, 0.80 
(0.49-0.94) 
525/544, 0.97 
(0.95-0.98) 
8/27, 0.30 525/527, 1.00 
TH ≥1:160 8/10, 0.80 
(0.49-0.94) 
530/544, 0.97 
(0.96-0.98) 
8/22, 0.36 530/532, 1.00 
TH ≥1:320 4/10, 0.40 
(0.17-0.69) 
533/544, 0.98 
(0.96-0.99) 
4/15, 0.27 533/539, 0.99 
TO ≥1:80 7/10, 0.70 
(0.40-0.89) 
528/544, 0.97 
(0.95-0.98) 
7/23, 0.30 528/531, 0.99 
TO ≥1:160 7/10, 0.70 
(0.40-0.89) 
530/544, 0.97 
(0.96-0.98) 
7/21, 0.33 530/533, 0.99 
TO ≥1:320 5/10, 0.50 
(0.24-0.76) 
537/544, 0.99 
(0.97-0.99) 
5/12, 0.42 537/542, 0.99 
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TABLE 4. Secondary analysis of the performance of a Widal anti-TH and -TO titer of ≥1:80 for typhoid 
fever diagnosis using group 1 as true positives and three different control groups as true negatives* 
* Group 1 were those with S. typhi isolated from blood culture (n=16), group 2 were those with non-typhi serotypes of S. 
enterica (NTS) isolated from blood culture (n=49), group 3 were those with pathogenic bacteria other than Salmonellae isolated 
from blood culture (n=113), and group 4 were those whose blood culture yielded no bacterial pathogen (n=1502).   
 
 
Comparison with earlier studies. We found 4 articles from 3 countries. In this series, the age group 
included and prevalence of blood-culture confirmed typhoid fever varied considerably. The cut-off titer 
used ranged  from ≥1:20 to ≥1:200 and the resulting sensitivity, specificity, PPV and NPV varied 
considerably (Table 5). 
 
Control group  Sensitivity 
(95%CI) 
Specificity (95%CI) Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
TH titer ≥1:80:     
Groups 2, 3, and 4 
(n=1664) 
12/16, 0.75 
(0.51-0.90) 
1630/1664, 0.98 
(0.97-0.99) 
12/46, 0.26 1630/1634, 
1.00 
Groups 2 and 3 (n=162) 12/16, 0.75 
(0.51-0.90) 
154/162, 0.95  
(0.91-0.97) 
12/20, 0.60 154/158, 0.97 
Group 3 (n=113) 12/16, 0.75 
(0.51-0.90) 
112/113, 0.99  
(0.95-1.00) 
12/13, 0.92 112/116, 0.97 
TO titer ≥1:80:      
Groups 2, 3, and 4 
(n=1664) 
11/16, 0.69 
(0.44-0.86) 
1631/1664, 0.98 
(0.97-0.99) 
11/44, 0.25 1631/1636, 
1.00 
Groups 2 and 3 (n=162) 11/16, 0.69 
(0.44-0.86) 
155/162, 0.96  
(0.91-0.98) 
11/18, 0.61 155/160, 0.97 
Group 3 (n=113) 11/16, 0.69 
(0.44-0.86) 
113/113, 1.00  
(0.97-1.00) 
11/11, 1.00 113/118, 0.96 
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Table 5 Summary of Widal performances in earlier studies 
 
 
 
 
Authors Date 
Study 
Country 
Sample 
Size 
Age 
classes 
included 
Prevalence 
of S. Typhi in 
participants 
Sensitivity Specificity PPV NPV 
Cut Off 
Titer 
Control Group(s) 
Gold 
Standard 
Choo et 
al. 
1993 Malaysia 2382 Children 6.1% 89% 89% <50% 99.2% 
O or H 
≥1:40 
Non-typhoid febrile 
children admitted to 
hospital 
Blood 
Culture 
Parry et 
al. 
1999 Vietnam 2000 
Children & 
Adults 
30.8% 
O: 49% 
H: 67%; 
O or H 
≥1:100:88% 
O: 97% 
H: 96%; 
O or H 
≥1:100:87% 
O: 88% 
H: 88%; 
O or H 
≥1:100:74% 
O: 82% 
H: 87%; 
O or H 
≥1:100:94% 
O:≥1:200 
H: ≥1:100; 
O or H 
≥1:100 
Lab confirmed malaria, 
dengue or bacteremia 
Blood 
Culture 
Wilke et 
al. 
2002 Turkey 410 ≥18 y 13.2% 
52% 
Post 7-10 d: 
90% 
88% 
Post 7-10 d: 
90% 
76% 
Post 7-10 d: 
88% 
71% 
Post 7-10 d: 
93% 
O: ≥1:200 
H: ≥1:200 
 
Healthy controls, 
nontyphoidal febrile 
patients, blood culture 
negative febrile cases 
 
Blood 
Culture, 
Stool 
Culture 
Olsen et 
al. 
2004 Vietnam 80 ≥3y 73.8% 
64% (field) 
61% (lab) 
76% (field) 
100% (lab) 
88% (field) 
100% (lab) 
43% (field) 
48% (lab) 
O or H 
≥1:100 
Lab confirmed 
bacteremia, AFB, dengue, 
malaria, pos. stool 
culture, pos. urine 
culture 
Blood 
Culture 
Ley et al. 
 
This 
study 
Tanzania 1680 2m. – 14y 1% 75% 98% 26% 100% H: ≥1:80 
Non-typhoid febrile 
children admitted to 
hospital 
Blood 
Culture 
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Discussion 
 
We found that a Widal titer of ≥1:80 was the optimal indicator of typhoid fever in our study 
population. The PPV, NPV and specificity in the primary analysis was more-or-less unchanged from 
the cut-off titers of ≥1:80 to ≥1:320, whereas the sensitivity was highest at a cut-off titer of ≥1:80. 
Although the Widal test at this cut-off titer performed relatively well in terms of sensitivity, 
specificity and NPV, its PPV was low. It has been argued that PPV is the most important measure of a 
clinical diagnostic method since it represents the proportion of patients with positive test results 
that are correctly diagnosed [13]. The PPV is not intrinsic to the test; it is affected by prevalence of 
the disease. In our setting, where 16 (1%) out of 1,680 febrile patients admitted to the pediatric 
ward had culture-proven typhoid fever, a negative Widal test result would have a good predictive 
value for the absence of disease but a positive result would have a low predictive value for typhoid 
fever, making the use of the Widal test in our setting questionable.  
In a previous paper describing the clinical aspects of the children included in this study [14] older age 
and long duration of fever were predictive of typhoid fever in this group. 
 
There are several difficulties associated with evaluation of the Widal test. Firstly, levels of agglutinins 
detectable in the non-infected populations of different areas vary considerably by time and place 
depending on the endemicity of the disease, which affects test performance. For example, the 
sensitivity and specificity of a Widal test anti-TO titer of 1:80 in Kolkata, India was 58% and 85% [10] 
compared to our findings of 69% and 98%. Secondly, test performance is also affected by cross-
reacting infections. In our study, none of the 113 children with non-Salmonella bacteremia exhibited 
titers above 1:80 for both O and H, although cross-reactions with Klebsiella spp. and Staphylococcus 
aureus [15] have been reported. In contrast, 7 (14.3%) of the 49 children with NTS had titers above 
1:80 for both O and H. There is also the possibility of cross-reactivity with non-bacterial infections 
such as malaria, dengue, hepatitis A, and infectious mononucleosis [2, 9, 16]. The third limitation is 
the choice of a satisfactory gold standard for diagnosis. We used blood culture-positive patients as 
our true positives. Although bone marrow culture would be the ideal gold standard, this test is 
difficult to perform in small rural hospitals in Africa. We found that 26 (1.7%) of 1,502 children from 
whom pathogenic bacteria were not isolated showed agglutination at 1:80 or higher, both for O and 
H antigens. These may be Widal false positive results due to cross-reaction. Alternatively, since the 
reported sensitivity of a single blood culture is only 40% to 60% [16, 17, 18, 19], some of these are 
likely to be false negative blood culture results. The final, and what we found to be the most 
contentious issue, is the selection of the most appropriate control group. It is difficult to choose 
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patients with febrile illness who are blood culture-negative and who definitely do not have typhoid 
fever. Furthermore, there were relatively few hospitalized children with no bacteremia in the same 
age range as those with typhoid fever. Thus, the control children were significantly younger than the 
cases. For our primary analysis, we used groups 2, 3 and 4 (i.e., all children admitted for a febrile 
illness who were subsequently culture-negative for S. typhi). These would be the most conservative 
controls for specificity since blood culture picks up only a fraction of typhoid cases, resulting in a 
control group that is likely contaminated with culture-negative typhoid cases. Despite this, the 
specificity of the Widal test was high. Using the more exclusive control groups as others had done 
previously [9, 10, 11] did not appreciably alter the sensitivity, specificity, and NPV but they increased 
the PPV. 
 
The previous studies included in our review (Table 5) had not been performed in Africa hence 
different cut – off titers were applied, and the resulting sensitivity, specificity, PPV and NPV varied 
considerably. PPV as well as NPV are dependent on the prevalence of disease within the group of 
participants; the selection process of study participants has therefore direct influence on the results. 
The difficulty of choosing the correct control group has been noted earlier [9]. While the gold 
standard, blood culture, is applied in most studies, the true negatives may be defined as febrile 
patients with a non-typhi laboratory-confirmed diagnosis as done by Parry et al. and Olsen et al. [9, 
20]. Alternatively, some studies use healthy controls. Choo et al [21]. considered all febrile cases 
with an S.typhi negative blood culture as the control group which is problematic as a number of 
blood culture-negative results are likely to be false-negative due to the poor sensitivity of the blood 
culture [17, 18, 19, 22].  Furthermore, it is difficult to compare the different test kits, as varying 
antigens perform differently [23]. 
 
Conclusion 
In summary, a Widal titer of ≥ 1:80 performed relatively well in terms of sensitivity and specificity.  
However, the low prevalence of typhoid fever of approximately 1% amongst children at Teule 
Hospital meant that the Widal test was only useful for excluding the disease.  
Considering the low cost of Widal testing and the absence of comparably cheap tests, Widal testing 
is likely to remain the test of choice in many developing country settings. But the need for rapid and 
cheap diagnostic tools with superior performance remains high. 
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Abstract 
Background: Typhoid fever remains a significant health problem in many developing countries. A 
rapid test with a performance comparable to that of blood culture would be highly useful. A rapid 
diagnostic test for typhoid fever, Tubex®, is commercially available that uses particle separation to 
detect immunoglobulin M directed towards Salmonella Typhi O9 lipopolysaccharide in sera.   
Methods: We assessed the sensitivity and specificity of the Tubex test among Tanzanian children 
hospitalized with febrile illness using blood culture as gold standard. Evaluation was done 
considering blood culture confirmed S. Typhi with non- typhi salmonella (NTS) and non – salmonella 
isolates as controls as well as with non-salmonella isolates only.  
Results: Of 139 samples tested with Tubex, 33 were positive for S. Typhi in blood culture, 49 were 
culture-confirmed NTS infections, and 57 were other non-salmonella infections. Thirteen hemolyzed 
samples were excluded. Using all non - S. Typhi isolates as controls, we showed a sensitivity of 79% 
and a specificity of 89%. When the analysis was repeated excluding NTS from the pool of controls we 
showed a sensitivity of 79% and a specificity of 97%. There was no significant difference in the test 
performance using the two different control groups (p>0.05).  
Conclusion: This first evaluation of the Tubex test in an African setting showed a similar performance 
to those seen in some Asian settings. Comparison with the earlier results of a Widal test using the 
same samples showed no significant difference (p>0.05) for any of the performance indicators, 
irrespective of the applied control group.  
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Background 
Typhoid fever remains a significant health problem in many developing countries. Estimates suggest 
an incidence rate of more than 21.5 million cases globally in the year 2000 [1]. Recent data from 
Tanzania mainland have found a strong variation of prevalence rates among blood culture positive 
isolates collected in local hospitals, ranging from 9% [2] to 21.4% [3] for Salmonella enterica serovar 
Typhi (S. Typhi), no data from Zanzibar are available to date. As the clinical picture of typhoid fever is 
often unspecific, misdiagnosis and insufficient or inadequate treatment are potential risks associated 
with the disease. In the absence of difficult-to-obtain bone marrow specimens, microbiologic culture 
of a blood sample is considered to be the current state-of-the art test for the diagnosis of typhoid 
fever even though its sensitivity may be as low as 40% [4; 5].  Culture may take up to seven days and 
requires a well-run and equipped laboratory, which is often not available in settings with endemic 
typhoid fever.  The widely in use Widal test provides a cost efficient alternative [6] for serological 
diagnosis, however its performance remains unsatisfying with sensitivity reported from Tanzania of 
75% using blood culture as the gold standard and applying a cut off titer of 1:80 [7]. The test further 
requires the establishment of a local cut off titer prior to use which is complicated. Therefore, a 
rapid test with a performance comparable to that of blood culture would be desirable.  
 
A rapid diagnostic test for typhoid fever, Tubex® is commercially available that uses particle 
separation to detect immunoglobulin M (IgM) directed towards Salmonella enterica serovar Typhi (S. 
Typhi) O9 lipopolysaccharide in patient sera. Performance of the test has previously been evaluated 
in a number of studies in Asia but none in Africa. Using blood culture results for comparison, we 
assessed the sensitivity and specificity of the Tubex test among Tanzanian children hospitalized with 
febrile illness and compared our results with those from previous studies. 
 
Methods 
For evaluation of the Tubex test, we used a selected subset of serum samples that was obtained for 
a fever surveillance study [2] from Teule Hospital in Muheza District, Tanzania. In order to 
accommodate the required sample size for the test validation, we included randomly selected and 
age-matched Salmonella enterica serotype Typhi (S. Typhi) positive serum samples from a second 
fever surveillance study conducted at Chake Chake Hospital in Pemba, Zanzibar. All samples were 
collected from children between the ages of 2 months to 14 years from 2008 to 2009.  
 
At Teule Hospital in Muheza, sera and blood was collected for culture from children with a history of 
three days of fever, or a history of less than three days of fever but with at least one of the following 
35 
severity criteria: respiratory distress; deep breathing; respiratory distress in combination with severe 
pallor; prostration; capillary refill ≥3 seconds; temperature gradient; systolic blood pressure <70 mm 
Hg;  coma defined by Glasgow Coma Scale (GCS) ≤ 10 or Blantyre Coma Scale (BCS) ≤ 2; severe 
jaundice; history of two or more convulsions in the last 24 hours; blood glucose <3 mmol associated 
with clinical signs; neck stiffness; bulging fontanel; or oxygen saturation <90%  [2]. 
 
At Chake Chake Hospital in Pemba, sera and blood was collected for culture from children with a 
recorded body temperature of >37.5°C for outpatients and any history of fever for inpatients.  
Duration of fever was not considered for study recruitment. 
 
About 3 to 5 milliliters (ml) of blood (depending on body weight) was collected and inoculated in a 
BactALERT™ Pediatric-fan bottle (Teule Hospital) or a BacTec Peds PLUS
 TM
/F bottle (Chake Chake 
Hospital) and incubated in the respective machine (BacT/ALERT 3D or BacTec 9050). Bacterial growth 
was evaluated following standard procedures. 
 
The Tubex® test (IDL – Sweden) was conducted according to the manufacturer’s instructions, which 
are as follows.  Forty-five microliters (μl) of antigen covered particles were added to the Tubex 
Reaction Well Strip and 45μl of non-hemolyzed serum was added. After two minutes of incubation 
time, 90μl of magnetic antibody coated solution was added, and the strip was sealed and shaken for 
two minutes. The strip was then placed on a magnetic tray for five minutes, separating the particles 
if a positive sample had been added. The resulting color change of the solution was read and 
categorized on a scale from 0 to 10. The results were interpreted as positive for scores of 4 or 
greater and as negative for scores of 2 or below as per the manufacturer’s instructions. Samples with 
a color corresponding to the value of 3 were interpreted as indeterminate. All blood culture isolates 
from individuals that matched the inclusion criteria and that were not considered a contaminant 
were included in the analysis. 
 
We performed the Tubex test on non-hemolyzed serum samples from the patients of the two 
surveillance studies who had blood culture-confirmed S. Typhi (defined as group 1), randomly 
selected cases of non-Typhi serotypes of S. enterica (NTS) (defined as group 2), and randomly 
selected cases with other (non-Salmonellae) pathogenic bacteria (defined as group 3). Staff 
members performing the Tubex test were blinded to the blood culture results.  
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For the analysis, sensitivity (true-positive rate) was defined as the probability that the Tubex test 
result will be positive when there is blood culture-confirmed typhoid fever (group 1) and specificity 
(true-negative rate) was defined as the probability that the Tubex® test result will be negative when 
S. Typhi is not isolated from blood culture (groups 2 and 3). We conducted a secondary analysis 
using only group 3 as the control group. Comparison of test performance using different control 
groups was done using the Yates Chi-Square Test corrected for continuity.  
 
We conducted a literature review in order to compare our findings with those from previous studies. 
We included studies of the Tubex test, which were identified by directly searching the MEDLINE 
database through PubMed. All articles since the first publication of the test [8] were included. We 
also conducted a supplementary search of references in retrieved articles. Abstracts were reviewed, 
and if relevant, the article was included.  
 
A comparison of performance of the Tubex® test with earlier published Widal test results obtained 
from the same samples was done using McNemar's Test for Correlated Proportions 
(http://faculty.vassar.edu).   
 
The fever surveillance studies at Chake-Chake and Teule Hospitals were approved by their respective 
local ethical review boards (Tanzania and Zanzibar), as well as by the International Vaccine Institute’s 
Institutional Review Board. Written informed consent was obtained from legal guardians of all 
participants prior to any sample or data collection. 
 
Results  
A total of 139 samples were tested with Tubex.  Thirty -three were found positive for S. Typhi in 
blood culture (group 1), 49 were culture-confirmed non-S. Typhi (NTS) infection (group 2), and 57 
were other non-Salmonella infections that were not contaminants (group 3).  Thirteen hemolyzed 
samples were excluded (Figure 1). 
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Figure 1: Specimen assembly 
 
 
*Age-matched, randomly selected 
**Randomly selected 
*** 17 from Zanzibar and 16 from Teule  
+
 Other bacterial growth included: 11x Escherichia coli, 10x Haemophilus influenzae type B, 8x Streptococcus pneumoniae, 
6x Pseudomonas spp., 5x Acinetobacter baumannii, 3x Streptococcus beta – hemolytic group A, 3x Haemophilus influenzae, 
2x Staphylcoccus aureus, 1x Burkholderia cepacia, 1x Streptococcus beta-hemolytic group C , 1x Campylobacter spp., 1x 
Pateurella multocida, 1x gram negative rods (not identified further), 1x Citrobacter braakii, 1x Stenotrophomonas, 1x 
Haemophilus parainfluenzae, 1x Streptococcus beta - hemolytic 
 
 
Of the 33 blood culture-positive S. Typhi cases, 26 had a positive Tubex result and were considered 
as true positives. Of the 106 blood culture confirmed NTS and non-salmonella cases (groups 2 and 
3), 94 yielded a negative Tubex result and were considered as true negatives. Considering only the 
57 non-Salmonella cases (group 3) as controls, resulted in 54 true negative cases.  
 
Using groups 2 and 3 as controls showed a sensitivity of 79% and a specificity of 89% (Table 1). The 
same analysis was repeated excluding NTS from the pool of controls and showed 79% and 97% for 
sensitivity and specificity, respectively. There was no significant difference in the test performance 
using the two different control groups (all were p>0.05 using the Chi square test).  
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Table 1: Performance of Tubex® using group 1 as true positives and two different control groups 
as true negatives 
 
 Control Group 
 Group 2 + 3*  Group 3*  
Sensitivity (95% CI) 
(absolute numbers) 
0.79 (0.52-0.81) 
(26/33) 
0.79 (0.62-0.90) 
(26/33) 
Specificity (95% CI) 
(absolute numbers) 
0.89 (0.81-0.94) 
(94/106) 
0.97 (0.85-0.99) 
(94/97) 
 
*Group 1 = S. Typhi (n=33), Group 2 = all non-yphi Salmonella (n=49), Group 3 = all blood culture-positive non-Salmonella 
cases (n=57) 
 
 
A total of 14 articles were retrieved and evaluated for inclusion into the review. All of the reported 
studies were performed in Asia; none in Africa. A total of six articles were excluded: two evaluated 
the test for non-typhoidal Salmonella [9] or S. Paratyphi [10], three did not evaluate the sensitivity 
and specificity of the test [11; 12; 13], and one was a letter to the editor [14]. Thus, eight 
publications were included in the review (Table 2). Five of the included articles reported findings of 
test performance that were similar to our results [15; 16; 17; 18; 19]. Two publications showed 
considerably lower sensitivity and specificity [20; 6], and one reported higher values [8] (Table 2). 
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Table 2: Comparison of the performance of the Tubex® test from published reports 
 
 
 
 
 
 
 
 
 
 
 
 
Author Year Journal 
Sam 
ple 
size 
Location 
Tubex
® cut 
off 
Sens Spec True neg. definition Reader Gold standard Study population 
Ley, B.  
et al  
This 
pape
r 
This 
Journal 
139 
Tanzania >4 
79% 89% 
All non- typhi 
bacteriamia 
Investigator Blood Culture (BACTEC) 
>2months + >37.5° (inpatients) & history 
of fever (outpatients) 
88 79% 97% 
All non- salmonella 
bacteriamia 
Naheed, 
A. et al 
2008 
Diagn 
Microbiol 
Infect 
Dis. 
867 Bangladesh ≥4 
60% 58% 
Other confirmed 
bacteremia 
ICDDRB lab Manual Blood Culture 
Active surveillance 
Temp ≥38°C 
60% 64% 
Blood culture neg & 
other bacteremia 
Rahman, 
M. et al 
2007 
Diagn 
Microbiol 
Infect 
Dis. 
243 Bangladesh > 4 
91.2% 82.3% 
Other febrile 
patients 
ICDDRB lab, 
min. 2 
independe
nt lab techs 
Manual Blood Culture 
Outpatients, all ages with history of 
fever 
No 
pos. 
89.5% Healthy subjects Healthy subjects 
Dong, B. 
et al 
2007 
Epidemio
l. Infect. 
1732 China 
≥2 100% 43% 
Paratyphoid cases - Blood culture (BACTEC) 
Age 5-60 with reported history of fever 
for 3 days 
≥4 69% 95% 
≥6 62% 95% 
≥8 23% 100% 
≥10 15% 100% 
Kawano, 
R. L. et al  
2006 JCM. 177 Philippines ≥2 94.7% 80.4% Blood culture neg. n/A Manual Blood Culture 
&BACTEC 
Clinically suspected typhoid cases 
Dutta, S. 
et al 
2006 
Diagn 
Microbiol 
Infect 
Dis. 
495 India ≥4 56% 88% Paratyphoid and 
malaria cases 
n/A Blood Culture BACTEC 
Outpatients, all ages, Pat with history of 
fever for 3 days 
Ohlsen, 
S. J. et al 
2004 JCM 79 Vietnam 
Accor
ding 
to 
proto
col 
78% 94% 
Other lab-confirmed 
febrile illnesses 
n/A 
Manual Blood Culture/ 
BACTEC 
Pat ≥3year and history of ≥ 4 day fever 
House, 
D. et al 
2001 JCM. 127 Vietnam >2 87% 76% 
Febrile hospitalized 
patients 
labtech Culture Children and adults 
Lim et al 1998 JCM 105 
Hong Kong 
& Malaysia 
>2 100% 100% 
Healthy individuals 
and pat with other 
bacterial diseases 
and autoimmune 
disease 
labtechs 
Culture confirmed (56% 
of pos.), clinical picture, 
various other tests 
Clinical picture, culture confirmed, 
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Discussion 
We found Tubex has a sensitivity of 79% using either control group (95%CI: 52-81% for groups 2 and 
3, and 62-90% for group 3 only) and a specificity of 89-97% (95%CI: 81-94% for groups 2 and 3 and 
85-99% for group 3 only) irrespective of control group. To our knowledge, this is the first evaluation 
of the test in an African population. Our results were similar to those observed in previous studies 
(five out of eight studies) in Asia assessing the performance of the test [15; 16; 17; 18; 19], though 
Kawano et al.  [17] and House et al. [19] used a lower cut-off titer than is recommended in the 
manual. In contrast, two studies [20; 6] found the performance of Tubex to be poorer than our 
findings, despite using a similar cut-off value, gold standard, and inclusion criteria.  The extremely 
good performance of Tubex observed by Lim et al. [8] has not been reproduced since.   
 
An important limitation of this study is that the sera are combined from two different patient 
populations and the purposeful selection of samples included in the three groups. During the 
preparation of the study, we calculated the sample sizes of true positive sera and true negative sera 
that are required for validation of the Tubex test and for comparison with the Widal test 
performance. The number of true positive sera from either hospital alone was insufficient for the 
validation. Thus, we included S. Typhi blood culture-confirmed sera from Pemba. Analysis of the 
results by hospital was not possible because of insufficient sample size.  
 
In a sub-analysis in assessing cross reactivity with NTS, blood culture-confirmed NTS cases were 
considered as true positives, and all other positive isolates, excluding S. Typhi, were considered as 
true negatives. In this sub-analysis Tubex had a sensitivity of 18% and a specificity of 95% (analysis 
not shown). 
Comparison with a Widal test that was earlier conducted using the same samples [7] revealed no 
significant difference (p>0.05) for any of the performance indicators, irrespective of the applied 
control group. But compared to the Widal test, Tubex is easier and quicker to perform. The Widal 
test requires 16 – 20 hours until the results are obtained while the complete procedure for the 
Tubex test is approximately 20 minutes. Tubex is more expensive at approximately 2.15 USD per test 
compared to <0.80 USD per test for the Widal tube agglutination test [6]. 
 
Interpreting the Tubex test results was found to be difficult and the results were prone to inter – 
reader variation. Assessing the color change according to the provided color scale requires 
experience and standardized good lighting conditions.  The Tubex test can only be applied to non-
hemolyzed and non-icteric serum samples, thus limiting its general application. However Tam et al. 
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[12] have described a method that includes a washing step and thereby addresses the problem of 
turbid serum. This method requires double the amount of antigen-coated particles as well as glycine 
buffered saline (GBS), thereby increasing the price per sample to approximately 4.50 USD and 
reducing its feasibility as an easy-to-perform test. While neither of the tests can be performed by 
untrained staff, interpretation of results is considered easier for the Widal test compared to Tubex. 
 
Conclusion 
The advantages of Tubex over the Widal test and the gold standard of blood culture is the short time 
it requires to obtain a result, and it does not require establishing a local cut-off value as with the 
Widal. In settings that can afford the relatively high cost of Tubex and that require instant individual 
diagnoses to support the clinical diagnosis of typhoid fever, Tubex is superior to the Widal tube 
agglutination test. For screening and surveillance purposes, as well as in settings with limited 
financial and technical resources, the Widal tube agglutination test is a possible alternative that can 
provide a similar performance as Tubex at a lower cost though it requires more time. Our evaluation 
of Tubex showed that any result must be handled with precaution. Results should be considered as 
indicative, not confirmatory. The test may be used to exclude disease though.  In conclusion, the 
need for a reliable, fast, cheap, and easy-to-apply rapid diagnostic test for typhoid fever remains in 
high demand.  
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Abstract 
Background. The gold standard for the diagnosis of cholera is stool culture, but this requires 
laboratory facilities and takes at least 24 hours. A rapid diagnostic test (RDT) that can be used by 
minimally trained staff at treatment centers could potentially improve the reporting and 
management of cholera outbreaks.  
 
Methods. We evaluated the Crystal VC™ RDT under field conditions in Zanzibar in 2009. Patients 
presenting to treatment centers with watery diarrhea provided a stool sample for rapid diagnostic 
testing. Results were compared to stool culture performed in a reference laboratory.  We assessed 
the overall performance of the RDT and evaluated whether previous intake of antibiotics, 
intravenous fluids, location of testing, and skill level of the technician affected the RDT results. 
 
Results. We included stool samples from 624 patients. Compared to culture, the overall sensitivity of 
the RDT was 93.1% (95%CI: 88.7 to 96.2%), specificity was 49.2% (95%CI: 44.3 to 54.1%), the positive 
predictive value was 47.0% (95%CI: 42.1 to 52.0%) and the negative predictive value was 93.6% 
(95%CI: 89.6 to 96.5%). The overall false positivity rate was 50.8% (213/419); fieldworkers frequently 
misread very faint test lines as positive. 
 
Conclusion. The observed sensitivity of the Crystal VC RDT evaluated was similar compared to earlier 
versions, while specificity was poorer.  The current version of the RDT could potentially be used as a 
screening tool in the field. Because of the high proportion of false positive results when field workers 
test stool specimens, positive results will need to be confirmed with stool culture.   
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Introduction 
Cholera remains a very common and potentially lethal disease in Asia and Africa.  Globally, more 
than 220,000 cases were reported to the World Health Organization (WHO) in 2009 [1], however the 
true number of cases, including unreported cases, is likely to be much higher – perhaps 3 -5 million 
cases / year [2]. Cholera occurs mainly in areas with poor infrastructure and limited access to clean 
water. The etiologic organisms, Vibrio cholerae O1 and O139, are highly transmissible and can cause 
explosive outbreaks. While many of those affected experience only mild symptoms, some suffer from 
severe disease characterized by profuse diarrhea, electrolyte imbalance, coma and death if prompt 
rehydration is not provided [3, 4]. Cholera cases have been reported from Zanzibar since 1978 with 
regular outbreaks documented since then [5, 6].  
 
The gold standard for laboratory confirmation of cholera is stool culture [7]. This is a routine 
procedure but requires laboratory infrastructure including trained staff. A single stool culture costs 
approximately 4 USD / case [8] and requires about 24 to 72 hours and transport to the closest 
sufficiently equipped laboratory, which may create additional costs. Furthermore, microbiologic 
facilities are often not available in locations where cholera occurs. A rapid diagnostic test (RDT) that 
is simple, easy to use and interpret, can be stored without refrigeration and is reasonably priced so 
that it can be deployed widely would be useful for the early confirmation of cholera outbreaks. 
Ideally, the RDT should be highly sensitive so as not to miss the diagnosis of cases and be sufficiently 
specific when used under actual field conditions [9]. Cholera confirmation would enable immediate 
implementation of control measures such as reactive vaccination [6], as well as more accurate 
reporting of the burden of the disease.  
 
A cholera RDT based on the detection of lipopolysaccharide (LPS) using gold particles was developed 
by the Institute Pasteur (IP). The RDT is a lateral flow immunochromatographic test for the 
qualitative determination of lipopolysaccharide antigen of both Vibrio cholerae O1 and O139 
serogroups from stool specimens using monoclonal antibodies specific to V. cholerae O1 and O139 
LPS.  Through a licensure agreement, the RDT is now being produced by Span Diagnostics (Surat, 
India) under the trade name Crystal VC™ at a price of 19.00 USD / test kit (10 test strips).  The test kit 
is stable at temperatures between 4°C to 30°C, and test strips are packed in waterproof pouches, 
allowing storage under high humidity conditions. Previous evaluations have been performed on the 
prototype and commercial versions of the RDT [10-15]. The primary objective of this study is to 
validate the current version of the Crystal VC™ RDT when performed by health workers in first-level 
treatment centers in Zanzibar.  We also sought to assess if the RDT results were affected by the skill 
level of the reader and previous intake of antibiotics or intravenous fluids. 
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Methods 
 
Ethics 
The study was conducted according to the principles expressed in the Declaration of Helsinki. 
Written informed consent was obtained from all participants. The Zanzibar Research Council Ethics 
Committee, the Institutional Review Board of the International Vaccine Institute, Seoul, Korea, and 
the Research Ethics Review Committee of the World Health Organization, Geneva, Switzerland 
approved this project. 
 
Study site  
The archipelago of Zanzibar lies about 50 kilometers east of mainland Tanzania and consists of two 
main islands, Unguja and Pemba, as well as smaller islets (Figure 1). In 2009, Zanzibar had a 
population of about 1.22 million [16]. Stool samples were collected at cholera treatment camps that 
were set up during outbreaks on the two main islands, Unguja and Pemba, in 2009. Treatment of 
patients was provided according to national guidelines. 
 
 
Figure 1: Study site 
 
 
 
 
 
Source: Google Maps 
 
 
Study procedures  
 
 
Acute watery diarrhea was defined as a minimum of three liquid, non-bloody, stools within 24 hours. 
Prior to presentation, no further inclusion / exclusion criteria were applied. Patients presenting with 
acute watery diarrhea were requested to provide a stool sample in a disposable plastic container. A 
swab was inserted into the stool sample and used to inoculate a tube of pre-packaged Cary Blair 
medium (EIKEN, Japan) for transport to the laboratory. About 200µl of stool from each sample was 
used for dipstick testing on site. A case report form (CRF) was completed to record frequency of 
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bowel movement over the previous 24 hours, antibiotics received, and fluid management 
(intravenous (IV) or oral rehydration solution (ORS)) provided at the health center. Bulk stool from a 
subset of patients attending a camp close to one of the participating laboratories was transported to 
the lab for additional testing on the same day as described below. 
 
Dipstick test 
The RDT was stored at room temperature and performed according to the package insert. Liquid 
stool was collected in a disposable plastic container. Approximately 200µl (4 drops) of stool were 
transferred with a disposable pipette to a disposable test tube provided with the kit. One drop of 
dilution buffer was added. The dipstick was inserted into the diluted stool and results were read 
within 15 – 20 minutes. The appearance of two bands on the dipstick, one control and one test, 
indicated that the stool sample was positive for V. cholerae. The appearance of only the control band 
indicated a negative sample. The non-appearance of the control band indicated a procedural error. 
Stool samples were tested under field conditions in the cholera treatment centers and in the 
laboratory as described below.  Dipstick results were recorded on the CRF, whereas laboratory 
results were recorded in separate laboratory forms. 
 
Performed under field conditions 
A local health worker in each cholera treatment camp performed the RDT after training and a copy of 
the English test kit manual containing illustrations on test procedure and interpretation had been 
provided. Training consisted of a theoretical session using a Power Point Presentation containing 
information on test procedures and schematic pictures of positive and negative test results based on 
the package insert. This was followed by a practical session during which the test was performed a 
number of times. All field workers where visited frequently in the field to ensure correct handling of 
the test. All local health workers had completed at least primary education and delivered basic 
medical services to attending diarrheal patients. Fieldworkers performed the test outdoors in 
daylight. 
 
Performed under laboratory conditions 
In order to assess the potential influence of environmental and light conditions, laboratory 
technicians were asked to repeat the test on bulk stool collected at the camps and to read the result 
independently. Stool culture results were not yet available at the time of the performance of the test 
and laboratory technicians were blinded as to the results of the RDT performed in the field, as well as 
the clinical picture of the patient. Two laboratory technicians performed the RDT after receiving 
training similar to the field workers and had received a copy of the test kit manual. The laboratory 
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technicians performed the test indoors using electric light sources.  All participating technicians had a 
diploma in laboratory sciences, which requires a minimum of one year of education, and had a 
minimum of three years working experience. 
 
Stool culture 
Upon arrival in the laboratory, samples from the Cary Blair media were streaked out on Thiosulphate 
Citrate Bile Sucrose Agar (TCBS; EIKEN, Japan), inoculated in alkaline peptone water (APW) and 
incubated at 37°C for 12 – 24 hours. If samples arrived as bulk stool, the samples were diluted in 
APW. An aliquot was streaked out on TCBS and the samples in APW and on TCBS were incubated for 
12 – 24 hours at 37°C. If no growth on TCBS was detected after incubation, an aliquot of the sample 
in APW was streaked out on TCBS and incubated again. If yellow colonies indicative of V. cholerae 
were detected on TCBS, motility indole ornithine agar (MIO) and triple sugar iron agar (TSI) were 
inoculated with colonies from TCBS and incubated for 18 hours at 37°C. In addition, a colony from 
TCBS was sub-cultivated on gelatin agar for later serological confirmation and incubated at 37°C 
overnight. If colonies indicative of V. cholerae were observed on TSI and MIO after incubation, 
colonies from gelatin agar were tested for agglutination reactions with O1 polyvalent, O1 Inaba, O1 
Ogawa and O139 antiserum (Beckton Dickinson, USA) as described elsewhere [17]. V. cholerae 
strains were transported to the National Institute of Cholera and Enteric Diseases in Kolkata, India 
where identification of the isolates was confirmed.  
 
Definitions, data management and analysis 
The CRF and laboratory results of each patient were computerized and linked using unique study 
identification numbers. The primary endpoint was the assessment of the performance of the RDT 
(done in the field) using microbiological stool culture result as the gold standard for comparison. 
Sensitivity (true-positive or TP rate) was defined as the probability that patients with laboratory-
confirmed cholera had a positive RDT. Specificity (true-negative or TN rate) was the probability that 
patients with no laboratory-confirmed cholera had a negative RDT. The positive predictive value 
(PPV) was the probability that patients with a positive RDT had V.cholerae isolated from stool 
culture. The negative predictive value (NPV) was the probability that patients with a negative RDT 
had no V.cholerae isolated from a stool culture.  The false positivity or FP rate (= FP / [FP + TN] or 1 – 
specificity) was the proportion of stool samples with no V. cholerae isolated on culture but showed a 
positive RDT result. The false negativity or FN rate (= FN / [TP + FN] or 1 – sensitivity) was the 
proportion of stool samples with V. cholerae isolated on culture but showed a negative RDT result. 
 
52 
 
We performed sub-group analyses by island (Pemba or Unguja), by previous recent intake versus 
non-intake of antibiotics and by receipt of intravenous fluids following previously published studies 
showing differences in RDT performance [13]. We defined recent intake of antibiotics as receipt of 
any oral or parenteral antimicrobial for the current illness prior to the collection of a stool sample.  
We classified fluid management at the treatment center as oral rehydration solution (ORS) or 
intravenous fluids (IVF) with or without ORS. To assess whether test validity was related to skill level 
of the reader and location of the testing, we compared the performance of the RDT when done in 
the field versus in the laboratory on a subset of samples. 
 
Comparison of unpaired samples was done using chi-square test; comparison of paired samples was 
done using McNemars test. Confidence intervals were calculated using exact method. Level of 
agreement was calculated using Cohen’s Kappa test for unweighted proportions. Calculations were 
done using Stata, version 10 (StataCorp, College Station, TX, USA). Performance indicators were 
calculated using Excel 2010 (Microsoft, WA, USA). 
 
Results: 
 
There were 624 patients who presented to a cholera treatment camp with acute watery diarrhea and 
were recruited into the study: 81 in Unguja and 543 in Pemba. We excluded 2 samples sent for 
culture but on which no RDT was done. A total of 622 stool samples were included in the analysis, 79 
(13%) from Unguja and 543 (87%) from Pemba residents (Figure 2).  
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Figure 2: Flow of study participants  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
624 patients presented to a treatment 
center with acute watery diarrhea and 
recruited into the study: 
 
• 81 in Unguja  
• 543 in Pemba 
 
 
622 patients included in the analysis 
 
• 79 in Unguja 
• 543 in Pemba 
Exclude  
• 0 refused to participatea 
• 2 patients  with stool culture 
but no RDT testing  
• 0 patients with RDT testing but 
no stool culture 
Culture results 
• 203 positive  
o 46 (Unguja) 
o 157 (Pemba 
• 419 negative 
o 33 (Unguja) 
o 386 (Pemba) 
 
RDT results 
• 402 positive  
o 57 (Unguja) 
o 345 (Pemba) 
• 220 negative 
o 22 (Unguja) 
o 198 (Pemba) 
 
54 
 
Performance of the RDT in the field 
Of the 622 stool samples, 203 (32.6%) yielded V. cholerae O1. No V. cholerae O139 was isolated. 
Using culture results as the gold standard, we calculated the sensitivity, specificity, PPV, and NPV of 
the RDT performed in the field for the diagnosis of cholera (Table 1). Overall sensitivity was 93.1% 
(95%CI: 88.7 to 96.2%), specificity was 49.2% (95%CI: 44.3 to 54.1%), the positive predictive value 
(PPV) was 47.0% (95%CI: 42.1 to 52.0%) and the negative predictive value (NPV) was 93.6% (95%CI: 
89.6 to 96.5%). The overall false positivity rate was 50.8% (213/419).  
 
Sub-group analyses of performance of the RDT in the field 
We evaluated the RDT performance by island (Table 1). V. cholerae was isolated from 46/79 or 58.2% 
of stool samples from Unguja compared to a significantly lower proportion of 157/543 or 28.9%, 
from Pemba (p<0.01). No significant differences in sensitivity, specificity and NPV of the RDT were 
observed between Unguja and Pemba, as well as between each island with the overall results (all 
p>0.05). However, we found a significant difference in PPV between Unguja and Pemba (71.9, 95%CI: 
58.5-83.0 versus 42.9, 95%CI: 37.6-48.3; p=0.02).  
 
Table 1: Performance of the cholera rapid diagnostic test, Pemba and Unguja, Zanzibar 
 
 
Sensitivity% 
(95%CI*) 
(TP/(TP+FN)) 
Specificity% 
(95%CI*) 
(TN/(TN+FP)) 
PPV% 
(95%CI*) 
(TP/(TP+FP)) 
NPV% 
(95%CI*) 
(TN/(TN+FN)) 
No. pos. / total (%) 
with V. cholera 
isolated on stool 
culture 
Total 
(n=622) 
93.1 
(88.7-96.2) 
(189/203) 
49.2 
(44.3-54.1) 
(206/419) 
47.0 
(42.1-52.0) 
(189/402) 
93.6 
(89.6-96.5) 
(206/220) 
203 / 622  
(32.6) 
Unguja 
(n=79) 
89.1 
(76.4-96.4) 
(41/46) 
51.5 
(33.5-69.2) 
(17/33) 
71.9 
(58.5-83.0) 
(41/57) 
77.3 
(54.6-92.2) 
(17/22) 
46 / 79  
(58.2) 
Pemba 
(n=543) 
94.3 
(89.4-97.4) 
(148/157) 
49.0 
(43.9-54.1) 
(189/386) 
42.9 
(37.6-48.3) 
(148/345) 
95.5 
(91.5-97.9) 
(189/198) 
157 / 543 
(28.9) 
p 0.82 0.87 0.02 0.53 <0.01 
*using exact method 
 
 
We compared the RDT performance by fluid management of patients: Rehydration treatment at the 
cholera camp was recorded for 592 / 622 (95.2%) participants (Table 2). Only 15.2% (32/210) of 
participants who received oral rehydration had a positive stool culture, compared with 43.2% 
(165/382) of those who received IV fluids (p<0.01). There were no statistically significant differences 
in sensitivity, specificity and NPV of RDT performance by fluids received (all p>0.05). However we 
again found a significant difference in PPV among those who received oral compared to IV 
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rehydration (26.8%, 95%CI: 18.9 to 36.0% versus 55.2%, 95%CI: 49.2 to 61.2%; p<0.01).  To evaluate 
whether the provided fluid treatment biased the field workers’ interpretation of the RDT results, we 
compared the false positivity rate by fluid management.  The false positivity rate was 46.1% among 
those who were orally rehydrated and 57.1% among those who were intravenously rehydrated 
(p=0.22). 
 
Information on prior antibiotic treatment was recorded for 576 / 622 (92.6%) participants. The 
percentage with a positive stool culture was 27.6% among those who had received antibiotics and 
32.2% among those who had not (p=0.60). We assessed whether previous antibiotic treatment 
affected the RDT performance (Table 2). Sensitivity, specificity, PPV and NPV did not vary significantly 
among recipients and non-recipients of antibiotics. The false positivity rate was 40.5% among those 
who had received antibiotics and 50.7% among those who had not (p=0.45).  
 
Table 2: Stratified analysis of the performance of cholera dipstick test according to fluid 
management (oral rehydration or intravenous fluids) in 592 patients and recent antibiotic intake 
(yes or no) in 576 patients  
 
 
Sensitivity 
(95%CI)* 
(TP/(TP+FN)) 
Specificity 
(95%CI)* 
(TN/(TN+FP)) 
PPV 
(95%CI)* 
(TP/(TP+FP)) 
NPV 
(95%CI)* 
(TN/(TN+FN)) 
No. pos. / total 
(%) with V. 
cholerae 
isolated on stool 
culture 
Fluid management (n=592) 
Oral 
rehydration 
n=210 
93.8 
(79.2-99.2) 
(30/32) 
53.9 
(46.3-61.4) 
(96/178) 
26.8 
(18.9-36.0) 
(30/112) 
98.0 
(92.8-99.8) 
(96/98) 
32** / 210(15.2) 
Intravenous 
rehydration 
n=382 
92.7 
(87.6-96.1) 
(153/165) 
42.9 
(36.2-49.7) 
(93/217) 
55.2 
(49.2-61.2) 
(153/277) 
88.6 
(80.9-94.0) 
(93/105) 
165** / 382 
(43.2) 
p 0.97 0.19 <0.01 0.62 <0.01 
Recent antibiotic (AB) intake (n=576) 
AB 
received 
n=58 
93.8 
(69.7-99.8) 
(15/16) 
59.5 
(43.3-74.4) 
(25/42) 
46.9 
(29.1-65.3) 
(15/32) 
96.2 
(80.4-99.9) 
(25/26) 
16 / 58 
(27.6) 
No AB 
received 
n=519 
92.8 
(87.8-96.2) 
(155/167) 
49.3 
(43.9-54.7) 
(173/351) 
46.5 
(41.1-52.1) 
(155/333) 
93.5 
(86.1-94.7) 
(173/190) 
167 / 518 
(32.2) 
p 0.98 0.48 0.98 0.86 0.60 
*using exact method 
** in 6/203 culture positive cases no rehydration treatment was provided 
Comparison of the performance of the RDT in the field versus in the laboratory 
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We compared the performance of RDT on a subset of 67/79 (84.8%) stool samples from Unguja 
tested both in the field and in the laboratory (Table 3).  In this subset, 40/67 (59.7%) samples yielded 
V. cholerae on culture. There was no statistically significant difference in the sensitivity, specificity 
PPV and NPV of the RDT’s performance (all p>0.05). The false positivity rate of the RDT was 45.4% in 
the field and 25.9% in the laboratory (Cohen’s kappa 0.8). 
 
Table 3: Comparison of the field and laboratory performance of the cholera dipstick test 
 
(n= 67 ) 
Sensitivity% 
(95%CI*) 
(TP/TP+FN) 
Specificity% 
(95%CI*) 
(TN/TN+FP) 
PPV% 
(95%CI*) 
(TP/TP+FP) 
NPV% 
(95%CI*) 
(TN/TN+FN) 
No. (%) with V. 
cholera isolated 
on stool culture** 
 
 
Field 
90.0 
(76.3-97.2) 
(36/40) 
55.6 
(35.3-74.5) 
(15/27) 
75.0 
(60.4-86.4) 
(36/48) 
78.9 
(54.4-93.9) 
(15/19) 
40 (59.7)  
 
Laboratory  
  
87.5 
(73.2-95.8) 
(35/40) 
74.1 
(53.7-88.9) 
(20/27) 
83.3 
(68.6-93.0) 
(35/42) 
80.0 
(59.3-93.2) 
(20/25) 
40 (59.7)  
P*** 0.931 0.510 0.740 0.977   
*using exact method  
**rapid diagnostic testing was done both in the field and in the laboratory on specimens from the same stool samples  
***using McNemars test 
 
 
Operational characteristics 
The test procedure, excluding sample collection, requires 20-25 minutes. The test kit manual 
provides clear instructions, and handling of the test was considered simple by field workers. Field 
workers found it easy to distinguish between valid and non-valid test results, based on the 
appearance of a control line. However, very faint positive test lines were interpreted as a positive 
result, but could not be confirmed by culture.  
 
Discussion 
 
We found an overall high sensitivity (93.1%) of the current version of the cholera RDT consistent with 
previous reports but a much poorer specificity (49.2%). Earlier studies were performed using a 
prototype dipstick – developed by the Institute Pasteur – and earlier versions of the commercial kit. 
Studies using the prototype versions of the RDT reported sensitivities in the range of 93% to 99% and 
specificities of 67%-97% [12-15]], whereas more recent reports on earlier versions of the commercial 
kit showed sensitivities of 92-97% and specificities of 71-76% [10, 11]. These studies not only varied 
by the RDT version used but also by the methodology and qualifications of the study personnel 
57 
 
performing the RDT (Table 4). There were also variations in the test procedure such as addition or 
non-addition of a buffer solution to the sample. In some studies, a 4-hour incubation step in alkaline 
peptone water was added. Overall, the prototype and precursor commercial kits performed better 
than the current version tested.  
 
The poor specificity of the current version of the commercial kit was associated with an overall false 
positive rate of 50.8%. The RDT’s false positivity rate when the RDT was read in the field was 44% 
versus 26% when done by laboratory technicians; possibly faint test lines on the dipsticks were over-
read by field workers as positive. We hypothesized whether patient characteristics (fluid 
management or receipt of antibiotics) biased the field workers’ interpretation of the RDT results. 
However, we found no significant differences in false positivity in these sub-group analyses. More 
likely the fieldworkers over-interpreted faint test lines which could be recognized in daylight but not 
in the indoor laboratory setting.  
 
Previously, Kalluri et al. assessed the impact of the reader’s qualification on the performance of the 
prototype test [12]. Laboratory technicians with several years of working experience as well as field 
workers with at least a college degree but no laboratory experience were asked to perform the test 
on 304 stool samples. The reported RDT sensitivities of 94% and 93% when done by laboratory 
technicians and field workers, respectively, were similar, but RDT specificity was higher when 
performed by the technicians (76% versus 67%) [12]. Harris et al. report a sensitivity of 97% and a 
specificity of 71-76%, when staff with graduate-level laboratory training performed the test in Guinea 
Bissau [10]. Mukherjee et al. reported a similar sensitivity and specificity (92% and 73%, respectively) 
when the test was done by graduate-level staff during a surveillance study at a hospital in Kolkata 
[11].  
 
In contrast to Wang et al., we did not find a higher sensitivity of the RDT when testing stool samples 
from patients receiving IVF compared to samples from patients who did not receive IVF [13]. 
However, we noted that the PPV in this study varied according to the proportion of culture-positive 
specimens. It has been argued that PPV is the most important measure of a clinical diagnostic 
method since it represents the proportion of patients with positive test results that are correctly 
diagnosed [18]. The PPV is not intrinsic to the test; it is affected by prevalence of the disease. For 
example, the PPV was 55% for samples from patients given IVF (43% of whom had V. cholerae 
isolated) while it was 27% for samples from patients managed with ORS (15% of whom had V. 
cholerae isolated). The PPV was 71.9% for the Unguja sub-sample with 58% cholera confirmation 
while for the Pemba sub-sample it was 43% with 29% cholera confirmation. In outbreak settings, 
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when a large proportion of patients presenting with acute watery diarrhea have cholera, a positive 
RDT result would have a good predictive value. In other situations (e.g. areas with seasonal cholera 
but also high rates of diarrheal diseases from other pathogens), the RDT may be less useful.  
 
Our study has several limitations. Firstly, a large sample from 622 study participants was available for 
the overall evaluation, but only 67 stool samples were used for sub-analyses. Secondly, while 
confirmation of V. cholerae isolates was performed at a reference laboratory, culture-negative stool 
samples were not validated further. In particular, we did not perform PCR testing on our RDT-
positive, culture-negative samples. Bhuiyan, et al. [14] analyzed five stool samples collected in 
Bangladesh by multiplex PCR that were O1 dipstick positive but culture-negative and found that all 
five were negative by PCR, indicating that the five dipstick-positive results were false positives. This is 
reassuring but does not entirely exclude the possibility of false negativity by stool culture. Thirdly, 
Alam et al. pointed out that the dipstick may detect non-culturable forms of V. cholerae that have 
transformed into a coccoid form due to unfavorable intra-host conditions, such as antibiotic 
treatment prior to testing [7]. We tried to assess the influence antibiotic treatment prior to sample 
collection may have had on our results but found no significant difference (p>0.05) in the false 
positive rates among participants who had taken antibiotics prior to sample collection and those who 
had not.  However, further research is needed to rule out the possibility that the RDT may detect V. 
cholerae antigen in some specimens which are culture negative.   
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Table 4: Validation studies of the Institut Pasteur prototype and Crystal VC™ test for diagnosis of Vibrio cholerae (O1 samples only considered) 
RDT Institut Pasteur prototype Crystal VC ™ (Span Diagnostics, India) 
Authors F Nato, et.al. [14] 
NA Bhuiyan, et.al. 
[13] 
X-Y Wang, et.al. [12] Kalluri, et.al. [11] J R Harris, et.al. [9] 
P. Mukherjee et al. 
[10] 
This Paper 
Journal, Year 
Clinical and 
Diagnostic Laboratory 
Immunology, 2003 
Journal of Clinical 
Microbiology, 2003 
BMC Infectious 
Diseases, 2006 
Tropical Medicine 
and International 
Health, 2006 
Tropical Medicine 
and International 
Health, 2009 
Japanese Journal of 
Infectious Diseases, 
2010 
This Journal 
Samples from Madagascar Bangladesh Mozambique Bangladesh Guinea-Bissau India Zanzibar / Tanzania 
Gold standard; 
type of stool 
samples used 
Culture of frozen 
stool or rapid cultures 
of stool collected on 
filter paper 
Culture  of rectal 
swab in C-B media 
(and multiplex PCR 
when RDT+/culture -) 
Culture of rectal 
swabs in C-B media  
and bulk stool 
Culture of  bulk stool 
PCR of swab in C-B 
media 
Culture of  bulk 
stool 
Culture of rectal swab in C-B 
media 
Type of stool 
samples for 
RDT testing 
frozen stool/rapid 
cultures of stool 
collected on filter 
paper 
Rectal swab 
incubated in APW at 
37°C for 4 h 
Rectal swab 
incubated in APW at 
37°C / 4 h and fresh, 
bulk stool 
Fresh, bulk stool Fresh, bulk stool Fresh, bulk stool Fresh, bulk stool 
RDT done by ? ? 
Trained technician at 
field laboratory 
Trained technician at 
ICDDR,B and trained 
field ‘paramedics’ 
Individuals with 
graduate-level 
laboratory technical 
training 
Post graduate 
investigator 
− Field worker at cholera 
treatment center (total) 
− Field worker at cholera 
treatment center (subset) 
− Laboratory technician (subset) 
No of samples 140 134 
− 219 rectal swabs  in 
APW 
− 172 bulk stool 
304 101 212 
− 622 (total) 
− 67(subset) 
No (%) 
positive for VC 
O1 by gold 
standard 
65 (46%) 68 (51%) 138 (35%) 116 (38%) 65 (64%) 72 (34%) 
− 203 (33%) (total) 
− 40 (60%) (subset) 
Sensitivity 98.5% 96% 
− 97% rectal swabs in 
APW 
− 93% bulk stool 
− 94% lab 
technicians 
− 93% field 
‘paramedics’ 
97% 92% 
− 93% (total) 
− 88% lab technician (subset) 
− 90% field worker (subset) 
Specificity 96% 92% 
− 97% rectal swabs in 
APW 
− 77%  bulk stool 
− 76% lab 
technicians 
− 67% by field 
‘paramedics 
71–76%; 73% 
− 49% (total) 
− 74% lab technician (subset) 
− 56% field worker (subset) 
PPV 95.6% 93% 
− 94% rectal swabs in 
APW 
− 74% bulk stool 
− 70% lab 
technicians 
− 63% field 
‘paramedics 
87–89% 64% 
− 47% (total) 
− 83% lab technician (subset) 
− 75% field worker (subset) 
NPV 99% 95% ? 
− 95% lab 
technicians 
− 94% field 
‘paramedics 
92–93% 95% 
− 94% (total) 
− 80% lab technician (subset) 
− 79% field worker (subset) 
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Conclusion 
 
 We found that field workers in this study who had basic general education but were not familiar 
with laboratory work experienced difficulties in interpreting the RDT performed in the cholera 
camps. If the RDT is to be deployed more widely, more extensive and repeated training may be 
required to improve the current RDT’s specificity. The test cannot replace stool culture and due to 
the high number of false positive results observed is not suitable to trigger an outbreak response in a 
resource poor setting. However the test may be potentially used as a screening tool. During cholera 
outbreaks, especially when several samples test positive, the test has an enhanced predictive value.  
Further research is needed to evaluate the accuracy of the RDT with specimens which have been 
incubated in APW for 4 to 6 hours prior to testing in the RDT since this procedure should dilute out 
the materials in stool samples which are causing the false positive results while amplifying the 
antigen signal from the V. cholerae.   
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Discussion: 
 
Neither of the evaluated tests performed at sensitivity and specificity ≥ 95%, the recommended level 
of performance for Malaria RDTs as suggested by the WHO (WHO, 2006). 
 
Table 1: Overview of test performance 
 
Test 
Sensitivity  
(%; 95% CI) 
Specificity  
(%; 95% CI) 
PPV NPV 
Widal 75 (51-90) 98 (97-99) 26* 100* 
Tubex 79 (52-81) 89 (81-94) 7** 100** 
Crystal VC 93 (89-96) 49 (44-54) 47*** 94*** 
*observed prevalence of 1% 
**calculated at 1% prevalence 
***observed prevalence of 33% 
 
Considering the main operational areas for RDTs, three fields for application can be identified: 
prospective diagnosis for treatment, retrospective diagnosis for surveillance purposes, and as a 
replacement for complicated and expensive laboratory procedures. 
 
In view of these areas, our findings do not support use of the Widal tube agglutination test for direct 
diagnostic purposes. The test performed best at a cut off titer of 1:80 for TH with an observed PPV of 
26% and an NPV of 100%. While a prevalence of 1% must be considered high (Crump et al, 2004) 
even at a higher prevalence of 5%, the PPV remains at 66%. The NPV is high at 100% and 99% 
respectively. 
Sensitivity and specificity of the Widal test were 75% and 98% respectively, figures which may be 
considered when creating correcting factors for surveillance data of samples from the region of 
Teule, Tanzania. However samples from Zanzibar, Tanzania, tested a year later with a different batch 
of the same test at the same laboratory and using a comparable gold standard showed sensitivity 
and specificity of 48% and 99% respectively at a cut off titre of 1:80 (TO and TH) (Thriemer et al, in 
preparation), which could suggest inter-batch variations.  
 
The TUBEX test showed a PPV of 7% at a prevalence of 1%, increasing to 27% at 5% prevalence, with 
an NPV of 100% and 81% respectively. The test is suitable to exclude typhoid fever, however chances 
of a correct positive result are low. Predictive values of the Tubex test were inferior to the Widal test 
at a higher price (2.15 USD vs. 0.50 USD). However the test provides a shorter time to result and does 
not require a setting and time specific validation study.    
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We found sensitivity and specificity of the Tubex test to be comparable (p>0.05) to the Widal test 
when tested on the same samples. Despite the superior operational characteristics of the Tubex, the 
Widal is preferable for RDT based surveillance in developing countries. 
 
Introducing either the Widal tube agglutination test or the Tubex test into routine microbiologic 
testing does not seem reasonable. Neither test performed at a level that would allow confident 
diagnosis. Both tests detect antibodies, serum samples tested can’t be analyzed for additional 
bacterial pathogens to the knowledge of the author. Since typhoid fever does not have a specific 
clinical picture (Thriemer et al, in preparation) which would allow to narrow down the number of 
samples assessed and thereby increase prevalence within the set of samples tested, neither test can 
be used as a final confirmation of disease due to the poor PPV observed . 
 
Since treatment of cholera and other watery diarrheal diseases is mostly through fluid replacement 
(Kasper et al, 2005b), the use of a cholera RDT in an outbreak setting does not provide a significant 
benefit to patient or caretaker. However a good diagnostic tool to detect the index case at the 
beginning of an outbreak would be of great public health benefit. Applying observed sensitivity and 
specificity at a low prevalence of 1% we calculated a PPV and NPV of 2% and 100% respectively; 
detecting the index case at the beginning of an outbreak with the Crystal VC is unlikely. 
Sensitivity and specificity of the Crystal VC were 93% and 49% respectively. In agreement with earlier 
studies (Kalluri et al, 2006) we observed a decrease in false positive test results when the test was 
performed by well trained staff. This favors using the test for surveillance purposes in a laboratory 
rather than as a diagnostic tool. 
Despite the low performance indicators observed for the Crystal VC, the test can be included into 
standard lab procedures using TCBS (Fig.1, 2).  
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Figure 1: Isolation of V. cholerae using serology for confirmation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted and modified from: Perilla, MJ. Ajello, G. Bopp, C. Elliott, J. Facklam, R. Knapp, JS. Popovic, T. Wells, J. Dowell, SF. (2003): Vibrio cholerae,  Manual for the Laboratory Identification and 
Antimicrobial Susceptibility Testing of Bacterial Pathogens of Public Health Importance in the Developing World, WHO & CDC, p.143 
Sample in Cary Blair 
Media 
APW, 37°C, 4-8h TCBS, 37°C, 12 – 24h 
TSI, 37°C, 18h MIO, 37°C, 18h 
Oxidase Test 
GA, 37°C, over night 
Polyvalent O1 Antiserum 
O139 Antiserum O1 Inaba Antiserum O1 Ogawa Antiserum 
Preserve in Nutrient Agar, dark, room temp. 
+ 
+ 
- 
+ 
TCBS – Thiosulfate Citrate Bile 
Sucrose 
APW- Alkaline Peptone Water 
TSI – Triple Sugar Iron 
MIO – Motility Indole Ornithine 
GA – Gelatin Agar 
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Figure 2: Isolation of V. cholerae using RDT for confirmation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TCBS, 37°C, 12-24h 
Sample in Cary Blair Medium 
RDT 
Preseve in NA, dark, room temp. 
APW, 37°C, 4-6h 
APW, 37°C, 12h 
TCBS -  Thiosulfate Citrate Bile Sucrose 
APW- Alkaline Peptone Water 
NA - Nutrient Agar 
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Since TCBS is a selective and differential medium that mainly supports growth of V. cholerae (Murray 
et al, 2007), any growth detected can be confirmed or excluded with the test. Prevalence within the 
sample set is likely to be high, resulting in a good PPV. Introducing the test into routine laboratory 
work in developing countries may reduce costs per sample by at least 2 USD. The test is easier and 
faster to perform than agglutination testing and will require very little quality control since the test is 
stable at room temperatures and to our knowledge no strong inter-batch variations have been 
reported to date. 
  
 
 
Conclusion 
None of the tests assessed performed well enough to be considered for diagnosis on its own.  Widal 
tube agglutination test, Tubex and the Crystal VC may however be considered for surveillance 
purposes if validation studies, including establishing a cut off titer for the Widal tube agglutination 
test, are conducted. A possible application for the Crystal VC is the confirmation of suspected V. 
cholerae colonies from TCBS.            
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Summary 
 
Introduction 
Typhoid fever and Cholera are poverty associated diseases and of major public health concern in 
developing countries.  For typhoid fever more than 21.000.000 cases at 1% fatality rate have been 
calculated for the year 2000, while cholera has an estimated incidence of 2.550.000 cases per year at 
a fatality rate of >8.2%. Lack of functioning infrastructure for fresh and waste water as arise in 
disaster zones and areas of high poverty are favoring conditions for both diseases. 
Effective vaccinations for both diseases exist, treatment through antibiotics (Typhoid fever) and fluid 
replacement (Cholera) can significantly reduce fatality rates. However neither is permanently 
available in many developing countries due to lack of funding as a result of reduced tax income due 
to disease. Lack of funding also results in lack of surveillance data for decision makers and lack of 
reliable diagnostic tools for caretakers. Time consuming and expensive laboratory based diagnosis is 
the gold standard for either disease, however these require well trained laboratory technicians. A 
possible solution are rapid diagnostic tests, if they are reliable, have convenient operational 
characteristics and are cheap. 
The aim of this cumulative thesis is to evaluate rapid diagnostic tests under developing country 
conditions and in outbreak settings. For this purpose we have assessed the widely in Africa in use 
Widal tube agglutination test (Span Diagnostics, India)  and the more recently developed Tubex test 
(IDL, Sweden) for typhoid fever as well as a rapid diagnostic test for Cholera (Span Diagnostics, India). 
 
Background 
Possibly the oldest rapid diagnostic test is the Widal test, based on a macroscopically visible 
agglutination reaction between patient antibodies and added antigen. The more recently developed 
Tubex test is based on an antibody inhibition reaction, resulting in a color change of a test-solution 
when serum is added and placed on a magnetic tray. The Crystal VC is a lateral flow immuno-
chromatographic test, detecting Vibrio cholera antigen.  
All three tests were evaluated by calculating the retrospective, prevalence independent, 
performance indicators sensitivity and specificity as well as the prospective, prevalence dependent, 
performance indicators positive and negative predictive value (PPV and NPV). In order to address 
poor sensitivity of the chosen gold standard, blood culture, different control groups were evaluated 
for the Widal and Tubex test. The Crystal VC was tested during cholera outbreaks in cholera camps. 
We also assessed the influence of degree of education of the reader for the Crystal VC.  
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Results 
 
Evaluation of the Widal tube agglutination test for the diagnosis of typhoid fever among children 
admitted to a rural hospital in Tanzania and a comparison with previous studies 
 
The Widal test is widely used in Africa but little information exists about its reliability.We therefore 
assessed the performance of the Widal tube agglutination test among febrile hospitalized Tanzanian 
children. We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive 
value (NPV) of various anti-TH and –TO titers using culture-confirmed typhoid fever cases as the 
“true positives” and all other febrile children with blood culture negative for S. Typhi as the “true 
negatives”. We founda 1% prevalence of culture proven typhoid fever within all participants 
(n=1,680). A single anti-TH titer of 1:80 and higher was the optimal indicator of typhoid fever at a 
sensitivity, specificity, NPV and PPV of 75%, 98%, 100%, and 26% respectively.  
We conclude that  a Widal titer of ≥ 1:80 performed best in terms of sensitivity, specificity, and NPV. 
However a test with improved PPV that is similarly easy to apply and cost-efficient is desirable 
 
 
Assessment and comparative analysis of a rapid diagnostic test (Tubex®) for the diagnosis of typhoid 
fever among hospitalized children in rural Tanzania 
 
A rapid diagnostic test for typhoid fever, Tubex®, is commercially available that uses particle 
separation to detect immunoglobulin M directed towards Salmonella Typhi O9 lipopolysaccharide in 
sera.   
We assessed the sensitivity and specificity of the Tubex test among Tanzanian children hospitalized 
(n=139) with febrile illness using blood culture as gold standard. Evaluation was done considering 
blood culture confirmed S. Typhi with non- typhi salmonella (NTS) and non – salmonella isolates as 
controls as well as with non-salmonella isolates only.  
 Considering all non - S. Typhi isolates controls, we observed sensitivity and specificity of 79% and 
89% respectively; considering only non-salmonella isolates as controls we did not observe a 
significant difference in performance (p>0,05).  
We found that this first evaluation of the Tubex test in an African setting provided similar 
performance indicators as have been reported earlier from Asia.. Comparison with the earlier results 
of a Widal test using the same samples showed no significant difference (p>0.05) for any of the 
performance indicators, irrespective of the applied control group.  
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Evaluation of a rapid dipstick (Crystal VC) for the diagnosis of cholera in Zanzibar and a comparison 
with previous studies 
 
We  evaluated a rapid diagnostic test for cholera (Crystal VC™) under field conditions in Zanzibar on 
patients presenting to treatment centers with watery diarrhea. The test was conducted on site, 
results were compared to stool culture results from the same samples performed in a nearby 
laboratory. We included 624 samples and found sensitivity of the RDT to be 93.1% (95%CI: 88.7 to 
96.2%), specificity was 49.2% (95%CI: 44.3 to 54.1%), the positive predictive value was 47.0% (95%CI: 
42.1 to 52.0%) and the negative predictive value was 93.6% (95%CI: 89.6 to 96.5%). The overall false 
positivity rate was 50.8% (213/419). 
While the observed sensitivity was similar compared to earlier versions of the test, specificity was 
poorer.  The current version of the RDT could potentially be used as a screening tool in the field. 
Because of the high proportion of false positive results when field workers test stool specimens, 
positive results will need to be confirmed with stool culture.   
 
Discussion 
Neither of the evaluated tests performed at a level sufficient to base treatment and therapy 
exclusively on the test result. While surveillance data can be based on test results for the Tubex test, 
a different batch of the same Widal test performed after the herein presented study showed poorer 
results (Thriemer et al, in preparation), which may be due to inter – batch variations. Neither test is 
suitable for introduction into routine laboratory work due to their underlying mechanism.  
PPV of the Crystal VC was found to be very poor, the test is not suitable for direct diagnostic 
purposes. The test can be integrated into surveillance systems if the very poor specificity is 
considered. A possible application of the test is in laboratory work, where the test can be used to 
confirm / exclude growth observed on the differential and selective medium TCBS. 
 
Conclusion 
None of the tests can be used for direct diagnosis. Widal, Tubex and the Crystal VC can be applied for 
surveillance purposes if validated on site. The Crystal VC may be a useful addition to routine 
laboratory work. 
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Zusammenfassung 
 
Einführung 
Sowohl Typhus als auch Cholera sind Armutsassoziierte Erkrankungen und stellen für die öffentliche 
Gesundheit vieler Entwicklungsländer eine ernste Bedrohung dar. Für das Jahr 2000 wurden mehr als 
21.000.000 Typhusfälle bei einer Sterblichkeitsrate von 1% berechnet; für Cholera gehen 
Schätzungen von einer jährlichen globalen Inzidenz von 2.550.000 Fällen bei einer Sterblichkeitsrate 
von >8.2% aus. Mangel an Trinkwasser und eine funktionierende Abwasserentsorgung, Bedingungen 
wie sie in Katastrophengebieten und vielen Entwicklungsländern herrschen, gelten als Hauptursache 
für die Verbreitung beider Krankheiten.. 
Wirksame Impfungen gegen beide Krankheiten existieren, effektive Therapien mit Antibiotika 
(Typhus) und Flüssigkeitssubstitution (Cholera) können die Sterblichkeitsraten in beiden Fällen 
signifikant senken. Allerdings sind weder Impfungen noch die benötigten Medikamente wegen 
chronischer Unterfinanzierung der Gesundheitssysteme in vielen Entwicklungsländern dauerhaft 
erhältlich. Eine mangelhafte Finanzierung ergibt sich teilweise aus geringem Steueraufkommen auf 
Grund verringerter krankheitsbedingter Arbeitskraft der Bevölkerung. Der Geldmangel hat außerdem 
eine Wissenslücke der Seuchenschutzbehörden über die eigentliche Höhe der Krankheitsfälle zur 
Folge und führt zu unzureichender Finanzierung diagnostischer Einrichtungen. 
  
Eine laborbasierte Diagnose für Typhus und Cholera ist zur Zeit der Gold Standard. Die dafür nötigen 
Verfahren sind jedoch teuer und können nur von gut ausgebildeten Labortechnikern durchgeführt 
werden. Diagnostische Schnelltests stellen eine Option dar, die diagnostischen Möglichkeiten in 
Entwicklungsländern zu verbessern. Dazu müssen diese Tests verlässliche Ergebnisse liefern, einfach 
in der Handhabung und kostengünstig sein. 
 
Das Ziel dieser kumulativen Dissertation war es daher, diagnostische Schnelltests in 
Entwicklungsländern und während mehrere Choleraausbrüche vor Ort auszuwerten. Dazu wurde der 
in Afrika weit verbreitete Widaltest (Span Diagnostics, Indien), der neuere Tubextest (IDL, Schweden) 
für die Diagnose von Typhus (S. Typhi) sowie ein Schnelltest für Cholera ausgewertet (Crystal VC, 
Span Diagnostics, Indien).        
 
Hintergrund 
Möglicherweise der älteste noch verwendete diagnostische Schnelltest ist der Widal Test. Dieser Test 
basiert auf einer makroskopisch sichtbaren Agglutinationsreaktion zwischen Antikörpern des 
Patienten in Serum und zugesetztem Antigen. Der wesentlich neuere Tubex Test basiert auf einer 
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Antikörper Inhibitionsreaktion, die zur Entfärbung einer Serum-Testlösung mittels Magnetismus 
führt. Der Crystal VC ist ein lateral flow immunochromatographischer Test zum Nachweis von Vibrio 
cholerae Antigen.  
Alle Tests wurden mit den retrospektiven, Prävalenz unabhängigen Indikatoren Sensitivität und 
Spezifität, sowie den prospektiven, Prävalenz abhängigen positiven und negativen prognostischen 
Werten  (PPV und NPV) bewertet. Da für den Widal- und Tubextest Blutkultur als Gold Standard 
gewählt wurde, wurden beide Tests mehrfach mit unterschiedlichen Kontrollgruppen ausgewertet 
um der geringen Sensitivität dieses Verfahrens Rechnung zu tragen. 
Der Crystal VC wurde während mehrerer Cholera Ausbrüche in staatlichen Krankenlagern getestet. Es 
wurde außerdem der Einfluss der Ausbildung des Testers auf das Testergebnis analysiert. 
 
Ergebnisse 
 
Beurteilung des Widal Tube Agglutination Tests zur Diagnose von Typhus (S. enterica Typhi) getestet 
an Proben von Kindern die in einem ländlichen Krankenhaus in Tansania aufgenommen wurden, 
sowie ein Vergleich mit früheren Studien  
 
Der Widal Test ist in Afrika weit verbreitet, obwohl wenig über seine Genauigkeit bekannt ist.Wir 
haben daher die Verlässlichkeit des Widal Tube Agglutination Tests an Serumproben von 
tansanischen Kindern getestet, die stationär aufgenommen worden waren. Wir haben Sensitivität, 
Spezifität, positiven prognostischen (PPV) und negativen prognostischen Wert (NPV) von 
verschiedenen TH und TO Titern berechnet. Als Berechnungsgrundlage haben wir durch Blutkultur 
bestätigte Typhus Fälle als „echte Positive Fälle“ und alle anderen fieberhaften Kinder die nicht an 
Typhus litten als „echte negative Fälle“ definiert. 
1% von 1680 Kindern hatte Typhus, bestätigt durch Blutkultur. Ein TH Titer von ≥1:80  war der beste 
Indikator für Typhus und zeigte eine Sensitivität von 75%, eine Spezifität von 98%,einen NPV von 
100% und einen PPV von 26%.. Ein Test mit einem verbesserten PPV der ähnlich einfach in 
Handhabung und im Preis ist wäre jedoch wünschenswert.       
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Beurteilung und vergleichende Analyse eines diagnostischen Schnelltests zur Diagnose von Typhus (S. 
Typhi) bei stationär aufgenommenen Kindern im ländlichen Tansania 
 
Ein diagnostischer Schnelltest für Typhus, Tubex®, der eine Partikel Separierung zum Nachweis von 
Immunoglobulin M gegen Salmonella Typhi O9 Lipopolysaccharid nutzt ist kommerziell erhältlich. 
Wir haben die Sensitivität und Spezifität des Tubex Test an Serumproben von stationär 
aufgenommenen Kindern (n=139) getestet die an einem fiebrigen Infekt litten. Gold Standard war 
Blutkultur. Durch Blutkultur bestätigte S. Typhi Fälle und nicht – Typhi Salmonellosen (NTS), sowie 
nicht – Salmonella Isolate wurden zur Auswertung herangezogen. 
Wir haben eine Sensitivität und Spezifität von 79% und 89% festgestellt. Bei einer zweiten Analyse, in 
der alle NTS Fälle aus der Kontrollgruppe ausgeschlossen wurden, ergab sich kein signifikanter 
Unterschied (p>0,05). Die erste Auswertung des Tests in Afrika ergab eine ähnliche Verlässlichkeit 
wie bereits früher beschriben worden ist. Ein Vergleich mit den Ergebnissen eines Widal Tests der an 
den gleichen Proben früher durchgeführt wurde ergab keinen signifikanten Unterschied unabhängig 
von der Definition der Kontrollgruppen.   
 
 
Beurteilung eines Schnelltests (Crystal VC) zur Diagnose von Cholera und ein Vergleich mit früheren 
Studien 
 
Wir haben einen diagnostischen Schnelltest für Cholera (Crystal VC™)  in Sansibar 2009 unter realen 
Bedingungen an Patienten mit wässrigem Durchfall getestet, die eine der örtlichen 
Gesundheitsstationen aufgesucht hatten. Der Schnelltest wurde vor Ort durchgeführt und mit den 
Ergebnissen einer Stuhlkultur verglichen die an den gleichen Proben durchgeführt wurde. Es wurden 
624 Stuhlproben in die Analyse mit einbezogen. Im Vergleich zur Stuhlkultur betrug die Sensitivität 
des RDT 93.1% (95%CI: 88.7 bis 96.2%), Spezifität war 49.2% (95%CI: 44.3 bis 54.1%), der Positive 
Prognostische Wert war 47.0% (95%CI: 42.1 bis 52.0%) und der Negative Prognostische Wert betrug 
93.6% (95%CI: 89.6 bis 96.5%). Insgesamt waren 50.8% (213/419) Testergebnisse falsch positiv. 
Die ermittelte Sensitivität entspricht  den Werten von Vorgängerversionen, die Spezifität war jedoch 
geringer. Eine mögliche Anwendung der aktuellen Version besteht in der Seuchenüberwachung vor 
Ort. Auf Grund der hohen Anzahl an falsch positiven Ergebnissen müssen positive Ergebnisse durch 
Stuhlkultur bestätigt werden.     
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Diskussion: 
Keiner der bewerteten Tests war verlässlich genug um eine entsprechende Behandlung oder 
Therapie auf Grundlage des Testergebnisses zu beginnen. Während eine Seuchenüberwachung 
basierend auf dem Tubex Test möglich ist, gilt dies nicht für den Widal Test. Nach Studienende wurde 
eine andere Charge des gleichen Widal Tests für eine ähnliche Studie eingesetzt und ergab 
wesentlich  schlechtere Ergebnisse (Thriemer et al, in Vorbereitung). Ein möglicher Grund könnten 
Qualitätsschwankungen bei der Produktion sein. Keiner der beiden Tests eignet sich zur Integration 
in die Labordiagnostik.  
Der für den Crystal VC ermittelte PPV war zu nieder um für die prognostische Diagnostik von Nutzen 
zu sein. Als Bestandteil einer Seuchenüberwachung und Erfassung von Cholera Fällen zu statistischen 
Zwecken stellt der Test eine mögliche Alternative dar, wenn die schlechte Spezifität berücksichtigt 
wird. Ein Anwendungsgebiet für den Test besteht in der Labordiagnostik. Bakterienkolonien die auf 
TCBS wachsen können mit dem Test als V. cholerae bestätigt werden.   
 
Conclusio 
Keiner der Tests stellt eine sinnvolle Ergänzung für die prognostische Diagnostik dar. Tubex und 
Crystal VC können in der Seuchenüberwachung eingesetzt werden. Der Crystal VC kann sinnvoll in 
der Labordiagnostik eingesetzt werden.          
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Abstract
Background: The diagnosis of typhoid fever is confirmed by culture of Salmonella enterica serotype Typhi (S. typhi). 
However, a more rapid, simpler, and cheaper diagnostic method would be very useful especially in developing 
countries. The Widal test is widely used in Africa but little information exists about its reliability.
Methods: We assessed the performance of the Widal tube agglutination test among febrile hospitalized Tanzanian 
children. We calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 
various anti-TH and -TO titers using culture-confirmed typhoid fever cases as the "true positives" and all other febrile 
children with blood culture negative for S. typhi as the "true negatives."
Results: We found that 16 (1%) of 1,680 children had culture-proven typhoid fever. A single anti-TH titer of 1:80 and 
higher was the optimal indicator of typhoid fever. This had a sensitivity of 75%, specificity of 98%, NPV of 100%, but PPV 
was only 26%. We compared our main findings with those from previous studies.
Conclusion: Among febrile hospitalized Tanzanian children with a low prevalence of typhoid fever, a Widal titer of ≥ 
1:80 performed well in terms of sensitivity, specificity, and NPV. However a test with improved PPV that is similarly easy 
to apply and cost-efficient is desirable.
Background
Salmonella enterica serotype Typhi (S. typhi), the caus-
ative agent of typhoid fever, was calculated to have caused
approximately 200,000 deaths globally in 2000 [1]. The
clinical picture of typhoid fever is nonspecific; confirmed
diagnosis through blood or bone-marrow culture
requires expensive and labor-intensive isolation and iden-
tification of the organism, which may take up to seven
days. A cheap and rapid alternative laboratory test is
desirable, especially for developing country settings
where typhoid fever is a major public health burden.
Various agglutination tests have been developed [2] of
which the Widal method is the oldest and remains the
most widely used. The test was first introduced by F.
Widal in 1896 [2] and is based on a macroscopically visi-
ble serum - mediated agglutination reaction between S.
typhi somatic lipopolysacharide O antigens (TO) and fla-
gellar H antigens (TH). Laboratories in industrialized
countries have stopped performing the assay. In Africa
the Widal test is still widely used [3] because typhoid
fever is perceived to be endemic in the area [3] and the
Widal test is the only rapid diagnostic assay that is avail-
able and affordable. The Widal test is commonly per-
formed when children and adults present with fever to
treatment centers, as few centers have the capacity to
perform micro-bacterial culture [4]. Despite this wide-
spread use, little has been published on its performance
in Africa.* Correspondence: bnley@ivi.int
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We assessed the sensitivity, specificity, positive predic-
tive value (PPV), and negative predictive value (NPV) of
the Widal tube agglutination test among Tanzanian chil-
dren hospitalized with febrile illness and compared our
results with those from previous studies.
Methods
Study site and population
The study was conducted as part of a childhood fever sur-
veillance study at Teule Hospital in Muheza district of
Northeastern Tanzania from 2008 to 2009. Muheza dis-
trict is located between the foothills of Kilimanjaro and
the coastal town of Tanga. The area is highly endemic for
Plasmodium falciparum malaria with perennial transmis-
sion and two seasonal peaks [5]. HIV sero-prevalence
among antenatal clinic attendees was about 7% in 2007
[6]. Teule Hospital is a busy 330-bed district-level general
hospital, serving a surrounding population of 277,000. It
has two 35-bed in-patient pediatric wards receiving
approximately 5,000 child admissions per year (2008).
Inclusion Criteria
Children aged 2 months to 14 years were screened for eli-
gibility during study hours from 7am to 7pm, Monday to
Sunday. Children with fever of 3 or more days prior to
admission, or fever of less than 3 days but with at least
one severity criteria (respiratory distress, deep breathing,
respiratory distress in combination with severe pallor,
prostration, capillary refill ≥ 3 seconds, temperature gra-
dient, systolic blood pressure < 70 mm Hg, coma defined
by Glasgow Coma Scale ≤ 10 or Blantyre Coma Scale ≤ 2,
severe jaundice, history of 2 or more convulsions in the
last 24 hours, blood glucose < 3 mmol associated with
clinical signs, neck stiffness, bulging fontanel, or oxygen
saturation < 90%) were recruited into the study. All clini-
cal information was recorded on a standard case record
form. Treatment was provided according to national
guidelines. On admission we collected 3 to 5 milliliters
(ml) of blood (depending on body weight) from each eli-
gible child for the Widal test and a single blood culture.
All clinical procedures were performed by trained study
clinical officers and nurses under the supervision of study
physicians.
Laboratory
Blood for culture was inoculated into BacT/ALERT™
Pediatric-fan bottles (bioMérieux, Marcy l'Etoile, France).
Inoculated blood culture bottles were transported imme-
diately to the hospital laboratory and incubated in the
BacT/ALERT 3 D automated microbial detection system.
Blood cultures were processed according to standard
methods. Colonies with biochemical reactions on API20E
suggestive of Salmonellae were confirmed serologically
by slide and tube agglutination testing using specific O
and H antisera (Becton Dickinson, NJ, USA).
A minimum of 0.5 ml of blood was separated to obtain
serum samples. All serum samples were frozen at -70°C
until Widal testing was done in three batches. Widal test-
ing was performed using standardized TO (IgM and IgG)
and TH (IgG) antigens (Stained Salmonella Antigens kit,
Span Diagnostics, India) according to standard methods
as described on the package insert. In brief, each sample
was diluted to a concentration of 1:40 with 0.9% NaCl in
two separate plastic tubes. A single drop of antigen was
added to the respective tube. Incubation times for both O
and H agglutinations were 16 to 20 hours at 37°C in a
water bath. Evaluation of test results was performed by at
least two lab technicians on an independent basis under
standardized light conditions. If agglutination was
detected in a sample, testing was done on that sample
diluted serially from 1:80 to 1:1280 for both O and H anti-
gens. All laboratory procedures were performed by
trained laboratory technicians under the supervision of
microbiologists. Technicians performing the Widal tests
were blinded to the participants' clinical picture and
blood culture results.
Data management
Case report forms were double-entered into custom-
made data entry programs using MS-Access (Microsoft
Corp.). Data management programs included error,
range, and consistency check programs. Analyses were
performed using EpiInfo v 3.4.3 (Centers for Disease
Control and Prevention, USA) and Stata TM v 10.0 (Stata
Corp., USA).
Definitions and analysis
Fever was defined as stated history or presence of fever of
≥37.5°C. Bacteremia was defined as fever with isolation of
pathogenic bacteria from blood culture. Children with a
febrile illness were classified as follows: those with S.
typhi subsequently isolated from blood culture (group 1),
those with non-Typhi serotypes of S. enterica (NTS) sub-
sequently isolated from blood culture (group 2), those
with pathogenic bacteria other than Salmonellae subse-
quently isolated from blood culture (group 3), and those
whose blood culture yielded no bacterial pathogen (group
4). Malaria status was not considered in the classification.
In areas of high transmission of P. falciparum where indi-
viduals develop immunity from previous episodes of
malaria starting at a young age, asymptomatic para-
sitemia is common and may be detected during febrile
episodes caused by another infection [7,8].
For the primary analysis, sensitivity (true-positive rate)
was defined as the probability that the Widal test result
would be positive when blood culture confirmed that
typhoid fever was present (group 1) and specificity (true-
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negative rate) was the probability that the Widal test
result would be negative when S. typhi was not isolated
from blood culture (groups 2, 3, and 4). The positive pre-
dictive value was the probability that culture-confirmed
typhoid was present when the test was positive, and the
negative predictive value was the probability that culture-
confirmed typhoid was not present when the test was
negative. Since serological tests detect antibody response
and perform better after a period of time from the onset
of the illness, sensitivity, specificity, PPV, and NPV were
also calculated separately for cases presenting with fever
for 5 days or less and for more than 5 days. Because con-
troversy exists about what is the most appropriate control
group to use [9-11], we conducted a secondary analysis
using two alternative "true-negative" control groups as
follows: those with NTS and other pathogenic bacteria
isolated from blood culture (groups 2 and 3), and those
with pathogenic bacteria other than Salmonellae isolated
from blood culture (group 3).
Comparisons were made using the Chi square or Fish-
ers' Exact test, as appropriate. Sensitivity, specificity, PPV,
and NPV were calculated according to standard methods.
The 95% confidence interval for sensitivity and specificity
was calculated using the Wilson's Score method [12].
Analyses were performed using EpiInfo v 3.4.3 (Centers
for Disease Control and Prevention, USA) and Stata TM v
10.0 (Stata Corp., USA).
Literature review
We conducted a literature review to compare our main
findings with those from previous studies of similar char-
acter. We included studies of the Widal test which were
identified by direct searches of the MEDLINE database
through PubMed. The searches were restricted to publi-
cations from 1993 to date. We also conducted supple-
mentary searches of the references in retrieved articles.
Abstracts were reviewed and if relevant, the article was
included.
Ethics
The fever surveillance was conducted following the prin-
ciples governing biomedical research involving human
subjects. Prior written informed consent was obtained
from the parent or guardian of all study participants. The
study protocol was approved by the National Institute of
Medical Research, Tanzania, and the International Vac-
cine Institute Institutional Review Board.
Results
The flow of patients is shown in Figure 1. A total of 1,706
febrile children were enrolled out of which 26 (1.5%) were
excluded for the following reasons: 19 or 1.1% had no
blood culture done, 6 or 0.4% had no Widal testing done
due to insufficient quantities of sera, and one case or 0.1%
had no blood culture nor Widal testing done. A total of
1,680 (98.5%) samples were included in the analysis.
There were 16 or 1.0% culture-confirmed typhoid fever
cases (group 1), 49 or 2.9% with NTS infection (group 2),
and 113 or 6.7% with non-Salmonella bacteremia (group
3). From 1,502 (89.4%) children, no pathogenic bacteria
were isolated from blood culture (group 4).
We assessed the age distribution and highest anti-TH
and -TO titer by blood culture-confirmed diagnosis
(Table 1). Children with typhoid fever were significantly
older compared to the other groups. Anti-TH agglutina-
tion titers of 1:80 and higher were detected among 12/16
(75.0%) culture-confirmed typhoid fever cases compared
to 7/49 (14.3%) of those with NTS infection, and 1/113
(0.9%) with other bacteremia (p values = 0.001 and <
0.001, respectively). Similarly, anti-TO agglutination
titers of 1:80 and higher were detected among 11/16
(68.8%) cases of typhoid fever compared to 7/49 (14.3%)
of those with NTS infection and 0/113 (0%) with other
bacteremia (p values < 0.001 and < 0.001, respectively).
Primary analysis
We calculated the sensitivity, specificity, PPV, and NPV of
various Widal test cut-offs for the diagnosis of typhoid
fever (Table 2). The sensitivity, specificity, PPV, and NPV
of an anti-TH titer of 1:80 were 75, 98, 26, and 100%,
respectively. The sensitivity, specificity, PPV, and NPV of
Figure 1 Flow of patients. *Species included: Streptococcus pneumo-
nia (n = 11), beta hemolytic Streptococci (n = 10), Staphylococcus au-
reus (n = 5), Haemophilus influenzae type b (n = 26), Escherichia coli (n = 
31), Acinetobacter species (n = 6), Non-fermenters (n = 12), Others: (n = 
5), Haemophilus parainfluenzae (n = 2), and Gram negative rods not 
identified (n = 5). **Species included: Bacillus (n = 22), Diphtheroids (n 
= 7), Micrococcus (n = 9), alpha-hemolytic Streptococcus viridans (n = 
4), coagulase negative Staphylococcus (n = 104), yeast (n = 5), mixed 
bacterial species (n = 4), Gram positive rods not identified (n = 1).
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an anti-TO titer of 1:80 were 69, 98, 25, and 100%, respec-
tively.
We compared the performance of the Widal test
between patients who presented with fever of 5 days or
less and those who presented with more than 5 days of
fever (Table 3). Of the 16 typhoid fever cases, 6 (37.5%)
presented with fever of 5 days or less, and 10 (62.5%) with
more than 5 days of fever. Of the 1,664 children in the
control group, 1,117 (67%) presented with fever of 5 days
or less and 544 (33%) with more than 5 days of fever.
Three control cases, whose fever duration was unknown,
were excluded from the analysis. The sensitivity of an
anti-TH and -TO titer of 1:80 increased, however not sig-
nificantly, from 67% to 80% and 67% to 70%, respectively,
with the longer duration of fever prior to admission (both
p > 0.05). The PPV of an anti-TH and -TO titer of 1:80
increased from 21% to 30% and 19% to 30% (both p >
0.05), respectively, with the longer duration of fever prior
to admission. But the change was also not statistically sig-
nificant.
Secondary analysis
Using different control groups, we compared the result-
ing sensitivity, specificity, PPV, and NPV of a Widal test
cut-off of an anti-TH and -TO titer of ≥1:80 for the diag-
nosis of typhoid fever (Table 4). Changing the control
group had no significant effect on the sensitivity, specific-
ity, and NPV but markedly increased the PPV of an anti-
TH titer of ≥1:80 from 26% to 92% and the PPV of an
anti-TO titer of ≥1:80 from 25% to 100%.
Comparison with earlier studies
We found 4 articles from 3 countries. In this series, the
age group included and prevalence of blood-culture con-
firmed typhoid fever varied considerably. The cut-off titer
used ranged from ≥1:20 to ≥1:200 and the resulting sensi-
tivity, specificity, PPV and NPV varied considerably
(Table 5).
Discussion
We found that a Widal titer of ≥1:80 was the optimal indi-
cator of typhoid fever in our study population. The PPV,
NPV and specificity in the primary analysis was more-or-
less unchanged from the cut-off titers of ≥1:80 to ≥1:320,
whereas the sensitivity was highest at a cut-off titer of
≥1:80. Although the Widal test at this cut-off titer per-
formed relatively well in terms of sensitivity, specificity
and NPV, its PPV was low. It has been argued that PPV is
the most important measure of a clinical diagnostic
method since it represents the proportion of patients
with positive test results that are correctly diagnosed [13].
The PPV is not intrinsic to the test; it is affected by preva-
lence of the disease. In our setting, where 16 (1%) out of
1,680 febrile patients admitted to the pediatric ward had
culture-proven typhoid fever, a negative Widal test result
would have a good predictive value for the absence of dis-
ease but a positive result would have a low predictive
value for typhoid fever, making the use of the Widal test
in our setting questionable.
In a previous paper describing the clinical aspects of
the children included in this study [14] older age and long
duration of fever were predictive of typhoid fever in this
group.
There are several difficulties associated with evaluation
of the Widal test. Firstly, levels of agglutinins detectable
in the non-infected populations of different areas vary
considerably by time and place depending on the ende-
micity of the disease, which affects test performance. For
example, the sensitivity and specificity of a Widal test
Table 2: Primary analysis for the performance* of the Widal test for typhoid fever diagnosis (n = 1680)
Widal titer Sensitivity (95%CI) Specificity (95%CI) Positive Predictive 
Value
Negative Predictive 
Value
TH ≥1:80 12/16, 0.75
(0.51-0.90)
1630/1664, 0.98
(0.97-0.99)
12/46, 0.26 1630/1634, 1.00
TH ≥1:160 11/16, 0.69
(0.44-0.86)
1639/1664, 0.98
(0.98-0.99)
11/36, 0.31 1639/1644, 1.00
TH ≥1:320 6/16, 0.38
(0.18-0.61)
1646/1664, 0.99
(0.98-0.99)
6/24, 0.25 1646/1656, 0.99
TO ≥1:80 11/16, 0.69
(0.44-0.86)
1631/1664, 0.98
(0.97-0.99)
11/44, 0.25 1631/1636, 1.00
TO ≥1:160 10/16, 0.63
(0.39-0.82)
1640/1664, 0.99
(0.98-0.99)
10/34, 0.29 1640/1646, 1.00
TO ≥1:320 6/16, 0.38
(0.18-0.61)
1652/1664, 0.99
(0.99-1.00)
6/18, 0.33 1652/1662, 0.99
*The values were calculated using culture-confirmed typhoid fever cases (group 1; n = 16) as the true positives and those cases from which 
S. typhi were not isolated from blood culture (groups 2, 3, and 4; n = 1664) as the true negatives.
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anti-TO titer of 1:80 in Kolkata, India was 58% and 85%
[10] compared to our findings of 69% and 98%. Secondly,
test performance is also affected by cross-reacting infec-
tions. In our study, none of the 113 children with non-
Salmonella bacteremia exhibited titers above 1:80 for
both O and H, although cross-reactions with Klebsiella
spp. and Staphylococcus aureus [15] have been reported.
In contrast, 7 (14.3%) of the 49 children with NTS had
titers above 1:80 for both O and H. There is also the pos-
sibility of cross-reactivity with non-bacterial infections
such as malaria, dengue, hepatitis A, and infectious
mononucleosis [2,9,16]. The third limitation is the choice
of a satisfactory gold standard for diagnosis. We used
blood culture-positive patients as our true positives.
Although bone marrow culture would be the ideal gold
standard, this test is difficult to perform in small rural
hospitals in Africa. We found that 26 (1.7%) of 1,502 chil-
dren from whom pathogenic bacteria were not isolated
showed agglutination at 1:80 or higher, both for O and H
antigens. These may be Widal false positive results due to
cross-reaction. Alternatively, since the reported sensitiv-
ity of a single blood culture is only 40% to 60% [16-19],
some of these are likely to be false negative blood culture
results. The final, and what we found to be the most con-
tentious issue, is the selection of the most appropriate
control group. It is difficult to choose patients with febrile
illness who are blood culture-negative and who definitely
do not have typhoid fever. Furthermore, there were rela-
tively few hospitalized children with no bacteremia in the
same age range as those with typhoid fever. Thus, the
control children were significantly younger than the
cases. For our primary analysis, we used groups 2, 3 and 4
Table 3: Comparison of the performance* of the Widal test for typhoid fever diagnosis by number of days of fever** prior to admission
Widal titer Sensitivity 
(95%CI)
Specificity (95%CI) Positive Predictive 
Value
Negative Predictive Value
≤ 5 days fever (n = 1123)
TH ≥1:80 4/6, 0.67
(0.30-0.90)
1102/1117, 0.99
(0.98-0.99)
4/19, 0.21 1102/1104, 1.00
TH ≥1:160 3/6, 0.50
(0.19-0.81)
1106/1117, 0.99
(0.98-0.99)
3/14, 0.21 1106/1109, 1.00
TH ≥1:320 2/6, 0.33
(0.10-0.70)
1110/1117, 0.99
(0.99-1.00)
2/9, 0.22 1110/1114, 1.00
TO ≥1:80 4/6, 0.67
(0.30-0.90)
1100/1117, 0.98
(0.98-0.99)
4/21, 0.19 1100/1102, 1.00
TO ≥1:160 3/6, 0.50
(0.19-0.81)
1107/1117, 0.99
(0.98-1.00)
3/13, 0.23 1107/1110, 1.00
TO ≥1:320 1/6, 0.17
(0.03-0.56)
1112/1117, 1.00
(0.99-1.00)
1/6, 0.17 1112/1117, 1.00
> 5 days fever (n = 554)
TH ≥1:80 8/10, 0.80
(0.49-0.94)
525/544, 0.97
(0.95-0.98)
8/27, 0.30 525/527, 1.00
TH ≥1:160 8/10, 0.80
(0.49-0.94)
530/544, 0.97
(0.96-0.98)
8/22, 0.36 530/532, 1.00
TH ≥1:320 4/10, 0.40
(0.17-0.69)
533/544, 0.98
(0.96-0.99)
4/15, 0.27 533/539, 0.99
TO ≥1:80 7/10, 0.70
(0.40-0.89)
528/544, 0.97
(0.95-0.98)
7/23, 0.30 528/531, 0.99
TO ≥1:160 7/10, 0.70
(0.40-0.89)
530/544, 0.97
(0.96-0.98)
7/21, 0.33 530/533, 0.99
TO ≥1:320 5/10, 0.50
(0.24-0.76)
537/544, 0.99
(0.97-0.99)
5/12, 0.42 537/542, 0.99
*The values were calculated using culture-confirmed typhoid fever cases (group 1; n = 16) as the true positives and those cases from which 
S. typhi were not isolated from blood culture (groups 2, 3, and 4; n = 1664) as the true negatives. **Three patients whose fever duration was 
unknown were excluded from the analysis.
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(i.e., all children admitted for a febrile illness who were
subsequently culture-negative for S. typhi). These would
be the most conservative controls for specificity since
blood culture picks up only a fraction of typhoid cases,
resulting in a control group that is likely contaminated
with culture-negative typhoid cases. Despite this, the
specificity of the Widal test was high. Using the more
exclusive control groups as others had done previously
[9-11] did not appreciably alter the sensitivity, specificity,
and NPV but they increased the PPV.
The previous studies included in our review (Table 5)
had not been performed in Africa hence different cut - off
titers were applied, and the resulting sensitivity, specific-
ity, PPV and NPV varied considerably. PPV as well as
NPV are dependent on the prevalence of disease within
the group of participants; the selection process of study
participants has therefore direct influence on the results.
The difficulty of choosing the correct control group has
been noted earlier [9]. While the gold standard, blood
culture, is applied in most studies, the true negatives may
be defined as febrile patients with a non-typhi laboratory-
confirmed diagnosis as done by Parry et al. and Olsen et
al. [9,20]. Alternatively, some studies use healthy controls.
Choo et al [21]. considered all febrile cases with an
S.typhi negative blood culture as the control group which
is problematic as a number of blood culture-negative
results are likely to be false-negative due to the poor sen-
sitivity of the blood culture [17-19,22]. Furthermore, it is
difficult to compare the different test kits, as varying anti-
gens perform differently [23].
Conclusion
In summary, a Widal titer of ≥ 1:80 performed relatively
well in terms of sensitivity and specificity. However, the
low prevalence of typhoid fever of approximately 1%
amongst children at Teule Hospital meant that the Widal
test was only useful for excluding the disease.
Considering the low cost of Widal testing and the
absence of comparably cheap tests, Widal testing is likely
to remain the test of choice in many developing country
settings. But the need for rapid and cheap diagnostic
tools with superior performance remains high.
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Table 4: Secondary analysis of the performance of a Widal anti-TH and -TO titer of ≥1:80 for typhoid fever diagnosis using group 1 as true 
positives and three different control groups as true negatives*
Control group Sensitivity (95%CI) Specificity (95%CI) Positive Predictive Value Negative Predictive Value
TH titer ≥1:80:
Groups 2, 3, and 4 
(n = 1664)
12/16, 0.75
(0.51-0.90)
1630/1664, 0.98
(0.97-0.99)
12/46, 0.26 1630/1634,
1.00
Groups 2 and 3 (n 
= 162)
12/16, 0.75
(0.51-0.90)
154/162, 0.95
(0.91-0.97)
12/20, 0.60 154/158, 0.97
Group 3 (n = 113) 12/16, 0.75
(0.51-0.90)
112/113, 0.99
(0.95-1.00)
12/13, 0.92 112/116, 0.97
TO titer ≥1:80:
Groups 2, 3, and 4 
(n = 1664)
11/16, 0.69
(0.44-0.86)
1631/1664, 0.98
(0.97-0.99)
11/44, 0.25 1631/1636,
1.00
Groups 2 and 3 (n 
= 162)
11/16, 0.69
(0.44-0.86)
155/162, 0.96
(0.91-0.98)
11/18, 0.61 155/160, 0.97
Group 3 (n = 113) 11/16, 0.69
(0.44-0.86)
113/113, 1.00
(0.97-1.00)
11/11, 1.00 113/118, 0.96
*Group 1 were those with S. typhi isolated from blood culture (n = 16), group 2 were those with non-typhi serotypes of S. enterica (NTS) isolated 
from blood culture (n = 49), group 3 were those with pathogenic bacteria other than Salmonellae isolated from blood culture (n = 113), and group 
4 were those whose blood culture yielded no bacterial pathogen (n = 1502).
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Assessment and comparative analysis of a rapid
diagnostic test (Tubex®) for the diagnosis of
typhoid fever among hospitalized children in
rural Tanzania
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Abstract
Background: Typhoid fever remains a significant health problem in many developing countries. A rapid test with a
performance comparable to that of blood culture would be highly useful. A rapid diagnostic test for typhoid fever,
Tubex®, is commercially available that uses particle separation to detect immunoglobulin M directed towards
Salmonella Typhi O9 lipopolysaccharide in sera.
Methods: We assessed the sensitivity and specificity of the Tubex test among Tanzanian children hospitalized with
febrile illness using blood culture as gold standard. Evaluation was done considering blood culture confirmed S.
Typhi with non-typhi salmonella (NTS) and non - salmonella isolates as controls as well as with non-salmonella
isolates only.
Results: Of 139 samples tested with Tubex, 33 were positive for S. Typhi in blood culture, 49 were culture-
confirmed NTS infections, and 57 were other non-salmonella infections. Thirteen hemolyzed samples were
excluded. Using all non - S. Typhi isolates as controls, we showed a sensitivity of 79% and a specificity of 89%.
When the analysis was repeated excluding NTS from the pool of controls we showed a sensitivity of 79% and a
specificity of 97%. There was no significant difference in the test performance using the two different control
groups (p > 0.05).
Conclusion: This first evaluation of the Tubex test in an African setting showed a similar performance to those
seen in some Asian settings. Comparison with the earlier results of a Widal test using the same samples showed
no significant difference (p > 0.05) for any of the performance indicators, irrespective of the applied control group.
Keywords: Salmonella, Tubex®, Widal, Africa, Rapid Diagnostic Test
Background
Typhoid fever remains a significant health problem in
many developing countries. Estimates suggest an incidence
rate of more than 21.5 million cases globally in the year
2000 [1]. Recent data from Tanzania mainland have found
a strong variation of prevalence rates among blood culture
positive isolates collected in local hospitals, ranging from
9% [2] to 21.4% [3] for Salmonella enterica serovar Typhi
(S. Typhi), no data from Zanzibar are available to date. As
the clinical picture of typhoid fever is often unspecific,
misdiagnosis and insufficient or inadequate treatment are
potential risks associated with the disease. In the absence
of difficult-to-obtain bone marrow specimens, microbiolo-
gic culture of a blood sample is considered to be the cur-
rent state-of-the art test for the diagnosis of typhoid fever
even though its sensitivity may be as low as 40% [4,5]. Cul-
ture may take up to seven days and requires a well-run
and equipped laboratory, which is often not available in
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settings with endemic typhoid fever. The widely in use
Widal test provides a cost efficient alternative [6] for sero-
logical diagnosis, however its performance remains unsa-
tisfying with sensitivity reported from Tanzania of 75%
using blood culture as the gold standard and applying a
cut off titer of 1:80 [7]. The test further requires the estab-
lishment of a local cut off titer prior to use which is com-
plicated. Therefore, a rapid test with a performance
comparable to that of blood culture would be desirable.
A rapid diagnostic test for typhoid fever, Tubex® is
commercially available that uses particle separation to
detect immunoglobulin M (IgM) directed towards Sal-
monella enterica serovar Typhi (S. Typhi) O9 lipopoly-
saccharide in patient sera. Performance of the test has
previously been evaluated in a number of studies in Asia
but none in Africa. Using blood culture results for com-
parison, we assessed the sensitivity and specificity of the
Tubex test among Tanzanian children hospitalized with
febrile illness and compared our results with those from
previous studies.
Methods
For evaluation of the Tubex test, we used a selected
subset of serum samples that was obtained for a fever
surveillance study [2] from Teule Hospital in Muheza
District, Tanzania. In order to accommodate the
required sample size for the test validation, we included
randomly selected and age-matched Salmonella enterica
serotype Typhi (S. Typhi) positive serum samples from a
second fever surveillance study conducted at Chake
Chake Hospital in Pemba, Zanzibar. All samples were
collected from children between the ages of 2 months to
14 years from 2008 to 2009.
At Teule Hospital in Muheza, sera and blood was col-
lected for culture from children with a history of three
days of fever, or a history of less than three days of
fever but with at least one of the following severity cri-
teria: respiratory distress; deep breathing; respiratory
distress in combination with severe pallor; prostration;
capillary refill ≥3 seconds; temperature gradient; systolic
blood pressure <70 mm Hg; coma defined by Glasgow
Coma Scale (GCS) ≤ 10 or Blantyre Coma Scale (BCS)
≤ 2; severe jaundice; history of two or more convulsions
in the last 24 hours; blood glucose <3 mmol associated
with clinical signs; neck stiffness; bulging fontanel; or
oxygen saturation <90% [2].
At Chake Chake Hospital in Pemba, sera and blood
was collected for culture from children with a recorded
body temperature of >37.5°C for outpatients and any
history of fever for inpatients. Duration of fever was not
considered for study recruitment.
About 3 to 5 milliliters (ml) of blood (depending on
body weight) was collected and inoculated in a BactA-
LERT™ Pediatric-fan bottle (Teule Hospital) or a
BacTec Peds PLUS ™/F bottle (Chake Chake Hospital)
and incubated in the respective machine (BacT/ALERT
3D or BacTec 9050). Bacterial growth was evaluated fol-
lowing standard procedures.
The Tubex® test (IDL - Sweden) was conducted
according to the manufacturer’s instructions, which are
as follows. Forty-five microliters (μl) of antigen covered
particles were added to the Tubex Reaction Well Strip
and 45 μl of non-hemolyzed serum was added. After
two minutes of incubation time, 90 μl of magnetic anti-
body coated solution was added, and the strip was
sealed and shaken for two minutes. The strip was then
placed on a magnetic tray for five minutes, separating
the particles if a positive sample had been added. The
resulting color change of the solution was read and
categorized on a scale from 0 to 10. The results were
interpreted as positive for scores of 4 or greater and as
negative for scores of 2 or below as per the manufac-
turer’s instructions. Samples with a color corresponding
to the value of 3 were interpreted as indeterminate. All
blood culture isolates from individuals that matched the
inclusion criteria and that were not considered a con-
taminant were included in the analysis.
We performed the Tubex test on non-hemolyzed
serum samples from the patients of the two surveillance
studies who had blood culture-confirmed S. Typhi
(defined as group 1), randomly selected cases of non-
Typhi serotypes of S. enterica (NTS) (defined as group
2), and randomly selected cases with other (non-Salmo-
nellae) pathogenic bacteria (defined as group 3). Staff
members performing the Tubex test were blinded to the
blood culture results.
For the analysis, sensitivity (true-positive rate) was
defined as the probability that the Tubex test result will
be positive when there is blood culture-confirmed
typhoid fever (group 1) and specificity (true-negative
rate) was defined as the probability that the Tubex® test
result will be negative when S. Typhi is not isolated
from blood culture (groups 2 and 3). We conducted a
secondary analysis using only group 3 as the control
group. Comparison of test performance using different
control groups was done using the Yates Chi-Square
Test corrected for continuity.
We conducted a literature review in order to compare
our findings with those from previous studies. We
included studies of the Tubex test, which were identified
by directly searching the MEDLINE database through
PubMed. All articles since the first publication of the
test [8] were included. We also conducted a supplemen-
tary search of references in retrieved articles. Abstracts
were reviewed, and if relevant, the article was included.
A comparison of performance of the Tubex® test with
earlier published Widal test results obtained from the
same samples was done using McNemar’s Test for
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Correlated Proportions http://faculty.vassar.edu/lowry/
VassarStats.html.
The fever surveillance studies at Chake-Chake and
Teule Hospitals were approved by their respective local
ethical review boards (Tanzania and Zanzibar), as well
as by the International Vaccine Institute’s Institutional
Review Board. Written informed consent was obtained
from legal guardians of all participants prior to any sam-
ple or data collection.
Results
A total of 139 samples were tested with Tubex. Thirty-
three were found positive for S. Typhi in blood culture
(group 1), 49 were culture-confirmed non-S. Typhi
(NTS) infection (group 2), and 57 were other non-Salmo-
nella infections that were not contaminants (group 3).
Thirteen hemolyzed samples were excluded (Figure 1).
Of the 33 blood culture-positive S. Typhi cases, 26
had a positive Tubex result and were considered as true
positives. Of the 106 blood culture confirmed NTS and
non-salmonella cases (groups 2 and 3), 94 yielded a
negative Tubex result and were considered as true nega-
tives. Considering only the 57 non-Salmonella cases
(group 3) as controls, resulted in 54 true negative cases.
Using groups 2 and 3 as controls showed a sensitivity
of 79% and a specificity of 89% (Table 1). The same
analysis was repeated excluding NTS from the pool of
controls and showed 79% and 97% for sensitivity and
specificity, respectively. There was no significant differ-
ence in the test performance using the two different
control groups (all were p > 0.05 using the Chi square
test).
A total of 14 articles were retrieved and evaluated for
inclusion into the review. All of the reported studies
were performed in Asia; none in Africa. A total of six
articles were excluded: two evaluated the test for non-
typhoidal Salmonella [9] or S. Paratyphi [10], three did
not evaluate the sensitivity and specificity of the test
[11-13], and one was a letter to the editor [14]. Thus,
eight publications were included in the review (Table 2).
 
 
 
 
 
 
 
 
*Age-matched, randomly selected 
**Randomly selected 
*** 17 from Zanzibar and 16 from Teule  
+
 Other bacterial growth included: 11x Escherichia coli, 10x Haemophilus influenzae type B, 8x Streptococcus pneumoniae, 6x Pseudomonas
spp., 5x Acinetobacter baumannii, 3x Streptococcus beta – hemolytic group A, 3x Haemophilus influenzae, 2x Staphylcoccus aureus, 1x
Burkholderia cepacia, 1x Streptococcus beta-hemolytic group C , 1x Campylobacter spp., 1x Pateurella multocida, 1x gram negative rods
(not identified further), 1x Citrobacter braakii, 1x Stenotrophomonas, 1x Haemophilus parainfluenzae, 1x Streptococcus beta - hemolytic 
189 serum samples with positive blood culture results from Teule 
13 excluded (hemolyzed) 
33 S. Typhi*** 
=> group 1 
57 other bacterial 
growth included** 
=> group 3 
49 Nontyphi  
=> group 2 
54  other bacterial 
growth excluded** 
17 serum samples with positive 
blood culture results for 
Salmonella Typhi from Pemba, 
Zanzibar* 
Figure 1 Specimen assembly.
Table 1 Performance of Tubex® using group 1 as true
positives and two different control groups as true
negatives
Control Group
Group 2 + 3* Group 3*
Sensitivity (95% CI) 0.79 (0.52-0.81) 0.79 (0.62-0.90)
(absolute numbers) (26/33) (26/33)
Specificity (95% CI) 0.89 (0.81-0.94) 0.97 (0.85-0.99)
(absolute numbers) (94/106) (94/97)
*Group 1 = S. Typhi (n = 33), Group 2 = all non-yphi Salmonella (n = 49),
Group 3 = all blood culture-positive non-Salmonella cases (n = 57).
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Five of the included articles reported findings of test
performance that were similar to our results [15-19].
Two publications showed considerably lower sensitivity
and specificity [20,6], and one reported higher values [8]
(Table 2).
Discussion
We found Tubex has a sensitivity of 79% using either
control group (95%CI: 52-81% for groups 2 and 3, and
62-90% for group 3 only) and a specificity of 89-97%
(95%CI: 81-94% for groups 2 and 3 and 85-99% for
Table 2 Comparison of the performance of the Tubex® test from published reports
Author Year Journal Sample
Size
Location Tubex®
cut off
Sens Spec True neg.
definition
Reader Gold
standard
Study
population
Ley, B. et
al
This
paper
This
Journal
139 Tanzania >4 79% 89% All non-typhi
bacteriamia
Investigator Blood Culture
(BACTEC)
>2 months +
>37.5°
(inpatients) &
history of
fever
(outpatients)
88 79% 97% All non-
salmonella
bacteriamia
Naheed,
A. et al
2008 Diagn
Microbiol
Infect Dis.
867 Bangladesh ≥4 60% 58% Other confirmed
bacteremia
ICDDRB lab Manual Blood
Culture
Active
surveillance
Temp ≥38°C
60% 64% Blood culture neg
& other
bacteremia
Rahman,
M. et al
2007 Diagn
Microbiol
Infect Dis.
243 Bangladesh >4 91.2% 82.3% Other febrile
patients
ICDDRB lab,
min. 2
independent
lab techs
Manual Blood
Culture
Outpatients,
all ages with
history of
fever
No.
Pos
89.5% Healthy subjects Healthy
subjects
Dong, B.
et al
2007 Epidemiol.
Infect.
1732 China ≥2 100% 43% Paratyphoid cases - Blood culture
(BACTEC)
Age 5-60
with reported
history of
fever for 3
days
≥4 69% 95%
≥6 62% 95%
≥8 23% 100%
≥10 15% 100%
Kawano,
R. L. et al
2006 JCM. 177 Philippines ≥2 94.7% 80.4% Blood culture
neg.
n/A Manual Blood
Culture
&BACTEC
Clinically
suspected
typhoid cases
Dutta, S.
et al
2006 Diagn
Microbiol
Infect Dis.
495 India ≥4 56% 88% Paratyphoid and
malaria cases
n/A Blood Culture
BACTEC
Outpatients,
all ages, Pat
with history
of fever for 3
days
Ohlsen,
S. J. et al
2004 JCM. 79 Vietnam According
to
protocol
78% 94% Other lab-
confirmed febrile
illnesses
n/A Manual Blood
Culture/
BACTEC
Pat ≥3 year
and history of
≥4 day fever
House,
D. et al
2001 JCM. 127 Vietnam >2 87% 76% Febrile
hospitalized
patients
labtech Culture Children and
adults
Lim et al 1998 JCM. 105 Hong
Kong &
Malaysia
>2 100% 100% Healthy
individuals and
pat with other
bacterial diseases
and autoimmune
disease
labtechs Culture
confirmed
(56% of pos.),
clinical picture,
various other
tests
Clinical
picture,
culture
confirmed,
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group 3 only) irrespective of control group. To our
knowledge, this is the first evaluation of the test in an
African population. Our results were similar to those
observed in previous studies (five out of eight studies) in
Asia assessing the performance of the test [15-19],
though Kawano et al. [17] and House et al. [19] used a
lower cut-off titer than is recommended in the manual.
In contrast, two studies [20,6] found the performance of
Tubex to be poorer than our findings, despite using a
similar cut-off value, gold standard, and inclusion cri-
teria. The extremely good performance of Tubex
observed by Lim et al. [8] has not been reproduced
since.
An important limitation of this study is that the sera
are combined from two different patient populations
and the purposeful selection of samples included in the
three groups. During the preparation of the study, we
calculated the sample sizes of true positive sera and true
negative sera that are required for validation of the
Tubex test and for comparison with the Widal test per-
formance. The number of true positive sera from either
hospital alone was insufficient for the validation. Thus,
we included S. Typhi blood culture-confirmed sera from
Pemba. Analysis of the results by hospital was not possi-
ble because of insufficient sample size.
In a sub-analysis in assessing cross reactivity with
NTS, blood culture-confirmed NTS cases were consid-
ered as true positives, and all other positive isolates,
excluding S. Typhi, were considered as true negatives. In
this sub-analysis Tubex had a sensitivity of 18% and a
specificity of 95% (analysis not shown).
Comparison with a Widal test that was earlier con-
ducted using the same samples [7] revealed no signifi-
cant difference (p > 0.05) for any of the performance
indicators, irrespective of the applied control group. But
compared to the Widal test, Tubex is easier and quicker
to perform. The Widal test requires 16 - 20 hours until
the results are obtained while the complete procedure
for the Tubex test is approximately 20 minutes. Tubex
is more expensive at approximately 2.15 USD per test
compared to <0.80 USD per test for the Widal tube
agglutination test [6].
Interpreting the Tubex test results was found to be
difficult and the results were prone to inter - reader var-
iation. Assessing the color change according to the pro-
vided color scale requires experience and standardized
good lighting conditions. The Tubex test can only be
applied to non-hemolyzed and non-icteric serum sam-
ples, thus limiting its general application. However Tam
et al. [12] have described a method that includes a
washing step and thereby addresses the problem of tur-
bid serum. This method requires double the amount of
antigen-coated particles as well as glycine buffered saline
(GBS), thereby increasing the price per sample to
approximately 4.50 USD and reducing its feasibility as
an easy-to-perform test. While neither of the tests can
be performed by untrained staff, interpretation of results
is considered easier for the Widal test compared to
Tubex.
Conclusion
The advantages of Tubex over the Widal test and the
gold standard of blood culture is the short time it
requires to obtain a result, and it does not require estab-
lishing a local cut-off value as with the Widal. In set-
tings that can afford the relatively high cost of Tubex
and that require instant individual diagnoses to support
the clinical diagnosis of typhoid fever, Tubex is superior
to the Widal tube agglutination test. For screening and
surveillance purposes, as well as in settings with limited
financial and technical resources, the Widal tube agglu-
tination test is a possible alternative that can provide a
similar performance as Tubex at a lower cost though it
requires more time. Our evaluation of Tubex showed
that any result must be handled with precaution. Results
should be considered as indicative, not confirmatory.
The test may be used to exclude disease though. In con-
clusion, the need for a reliable, fast, cheap, and easy-to-
apply rapid diagnostic test for typhoid fever remains in
high demand.
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Abstract
Background: The gold standard for the diagnosis of cholera is stool culture, but this requires laboratory facilities and takes
at least 24 hours. A rapid diagnostic test (RDT) that can be used by minimally trained staff at treatment centers could
potentially improve the reporting and management of cholera outbreaks.
Methods: We evaluated the Crystal VCTM RDT under field conditions in Zanzibar in 2009. Patients presenting to treatment
centers with watery diarrhea provided a stool sample for rapid diagnostic testing. Results were compared to stool culture
performed in a reference laboratory. We assessed the overall performance of the RDT and evaluated whether previous
intake of antibiotics, intravenous fluids, location of testing, and skill level of the technician affected the RDT results.
Results: We included stool samples from 624 patients. Compared to culture, the overall sensitivity of the RDT was 93.1%
(95%CI: 88.7 to 96.2%), specificity was 49.2% (95%CI: 44.3 to 54.1%), the positive predictive value was 47.0% (95%CI: 42.1 to
52.0%) and the negative predictive value was 93.6% (95%CI: 89.6 to 96.5%). The overall false positivity rate was 50.8% (213/
419); fieldworkers frequently misread very faint test lines as positive.
Conclusion: The observed sensitivity of the Crystal VC RDT evaluated was similar compared to earlier versions, while
specificity was poorer. The current version of the RDT could potentially be used as a screening tool in the field. Because of
the high proportion of false positive results when field workers test stool specimens, positive results will need to be
confirmed with stool culture.
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Introduction
Cholera remains a very common and potentially lethal disease
in Asia and Africa. Globally, more than 220,000 cases were
reported to the World Health Organization (WHO) in 2009 [1],
however the true number of cases, including unreported cases, is
likely to be much higher – perhaps 3–5 million cases/year [2].
Cholera occurs mainly in areas with poor infrastructure and
limited access to clean water. The etiologic organisms, Vibrio
cholerae O1 and O139, are highly transmissible and can cause
explosive outbreaks. While many of those affected experience only
mild symptoms, some suffer from severe disease characterized by
profuse diarrhea, electrolyte imbalance, coma and death if prompt
rehydration is not provided [3,4]. Cholera cases have been
reported from Zanzibar since 1978 with regular outbreaks
documented since then [5,6].
The gold standard for laboratory confirmation of cholera is
stool culture [7]. This is a routine procedure but requires
laboratory infrastructure including trained staff. A single stool
culture costs approximately 4 USD/case [8] and requires about 24
to 72 hours and transport to the closest sufficiently equipped
laboratory, which may create additional costs. Furthermore,
microbiologic facilities are often not available in locations where
cholera occurs. A rapid diagnostic test (RDT) that is simple, easy
to use and interpret, can be stored without refrigeration and is
reasonably priced so that it can be deployed widely would be
useful for the early confirmation of cholera outbreaks. Ideally, the
RDT should be highly sensitive so as not to miss the diagnosis of
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cases and be sufficiently specific when used under actual field
conditions [9]. Cholera confirmation would enable immediate
implementation of control measures such as reactive vaccination
[6], as well as more accurate reporting of the burden of the disease.
A cholera RDT based on the detection of lipopolysaccharide
(LPS) using gold particles was developed by the Institute Pasteur
(IP). The RDT is a lateral flow immunochromatographic test for
the qualitative determination of lipopolysaccharide antigen of both
Vibrio cholerae O1 and O139 serogroups from stool specimens using
monoclonal antibodies specific to V. cholerae O1 and O139 LPS.
Through a licensure agreement, the RDT is now being produced
by Span Diagnostics (Surat, India) under the trade name Crystal
VCTM at a price of 19.00 USD/test kit (10 test strips). The test kit
is stable at temperatures between 4uC to 30uC, and test strips are
packed in waterproof pouches, allowing storage under high
humidity conditions. Previous evaluations have been performed
on the prototype and commercial versions of the RDT [10–15].
The primary objective of this study is to validate the current
version of the Crystal VCTM RDT when performed by health
workers in first-level treatment centers in Zanzibar. We also sought
to assess if the RDT results were affected by the skill level of the
reader and previous intake of antibiotics or intravenous fluids.
Methods
Ethics
The study was conducted according to the principles expressed
in the Declaration of Helsinki. Written informed consent was
obtained from all participants. The Zanzibar Research Council
Ethics Committee, the Institutional Review Board of the
International Vaccine Institute, Seoul, Korea, and the Research
Ethics Review Committee of the World Health Organization,
Geneva, Switzerland approved this project.
Study site
The archipelago of Zanzibar lies about 50 kilometers east of
mainland Tanzania and consists of two main islands, Unguja and
Pemba, as well as smaller islets (Figure 1). In 2009, Zanzibar had a
population of about 1.22 million [16]. Stool samples were collected
at cholera treatment camps that were set up during outbreaks on
the two main islands, Unguja and Pemba, in 2009. Treatment of
patients was provided according to national guidelines.
Study procedures
Acute watery diarrhea was defined as a minimum of three
liquid, non-bloody, stools within 24 hours. Prior to presentation,
no further inclusion/exclusion criteria were applied. Patients
presenting with acute watery diarrhea were requested to provide a
stool sample in a disposable plastic container. A swab was inserted
into the stool sample and used to inoculate a tube of pre-packaged
Cary Blair medium (EIKEN, Japan) for transport to the
laboratory. About 200 ml of stool from each sample was used for
dipstick testing on site. A case report form (CRF) was completed to
record frequency of bowel movement over the previous 24 hours,
antibiotics received, and fluid management (intravenous (IV) or
oral rehydration solution (ORS)) provided at the health center.
Bulk stool from a subset of patients attending a camp close to one
of the participating laboratories was transported to the lab for
additional testing on the same day as described below.
Dipstick test. The RDT was stored at room temperature and
performed according to the package insert. Liquid stool was
collected in a disposable plastic container. Approximately 200 ml
(4 drops) of stool were transferred with a disposable pipette to a
disposable test tube provided with the kit. One drop of dilution
buffer was added. The dipstick was inserted into the diluted stool
and results were read within 15–20 minutes. The appearance of
two bands on the dipstick, one control and one test, indicated that
the stool sample was positive for V. cholerae. The appearance of only
the control band indicated a negative sample. The non-appear-
ance of the control band indicated a procedural error. Stool
samples were tested under field conditions in the cholera treatment
centers and in the laboratory as described below. Dipstick results
were recorded on the CRF, whereas laboratory results were
recorded in separate laboratory forms.
a. Performed under field conditions. A local health worker in
each cholera treatment camp performed the RDT after
training and a copy of the English test kit manual containing
illustrations on test procedure and interpretation had been
provided. Training consisted of a theoretical session using a
Power Point Presentation containing information on test
procedures and schematic pictures of positive and negative
test results based on the package insert. This was followed by a
practical session during which the test was performed a
number of times. All field workers where visited frequently in
the field to ensure correct handling of the test. All local health
workers had completed at least primary education and
delivered basic medical services to attending diarrheal
patients. Fieldworkers performed the test outdoors in daylight.
b. Performed under laboratory conditions. In order to assess the
potential influence of environmental and light conditions,
laboratory technicians were asked to repeat the test on bulk
stool collected at the camps and to read the result
independently. Stool culture results were not yet available at
the time of the performance of the test and laboratory
technicians were blinded as to the results of the RDT
performed in the field, as well as the clinical picture of the
patient. Two laboratory technicians performed the RDT after
receiving training similar to the field workers and had received
a copy of the test kit manual. The laboratory technicians
performed the test indoors using electric light sources. All
participating technicians had a diploma in laboratory sciences,
which requires a minimum of one year of education, and had
a minimum of three years working experience.
Stool culture. Upon arrival in the laboratory, samples from the
Cary Blair media were streaked out on Thiosulphate Citrate Bile
Sucrose Agar (TCBS; EIKEN, Japan), inoculated in alkaline
peptone water (APW) and incubated at 37uC for 12–24 hours. If
samples arrived as bulk stool, the samples were diluted in APW.
An aliquot was streaked out on TCBS and the samples in APW
and on TCBS were incubated for 12–24 hours at 37uC. If no
growth on TCBS was detected after incubation, an aliquot of the
sample in APW was streaked out on TCBS and incubated again. If
yellow colonies indicative of V. cholerae were detected on TCBS,
motility indole ornithine agar (MIO) and triple sugar iron agar
(TSI) were inoculated with colonies from TCBS and incubated for
18 hours at 37uC. In addition, a colony from TCBS was sub-
cultivated on gelatin agar for later serological confirmation and
incubated at 37uC overnight. If colonies indicative of V. cholerae
were observed on TSI and MIO after incubation, colonies from
gelatin agar were tested for agglutination reactions with O1
polyvalent, O1 Inaba, O1 Ogawa and O139 antiserum (Beckton
Dickinson, USA) as described elsewhere [17]. V. cholerae strains were
transported to the National Institute of Cholera and Enteric
Diseases in Kolkata, India where identification of the isolates was
confirmed.
Evaluation of a Rapid Diagnostic Test for Cholera
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Definitions, data management and analysis
The CRF and laboratory results of each patient were
computerized and linked using unique study identification
numbers. The primary endpoint was the assessment of the
performance of the RDT (done in the field) using microbiological
stool culture result as the gold standard for comparison. Sensitivity
(true-positive or TP rate) was defined as the probability that
patients with laboratory-confirmed cholera had a positive RDT.
Specificity (true-negative or TN rate) was the probability that
patients with no laboratory-confirmed cholera had a negative
RDT. The positive predictive value (PPV) was the probability that
patients with a positive RDT had V.cholerae isolated from stool
culture. The negative predictive value (NPV) was the probability
that patients with a negative RDT had no V.cholerae isolated from a
stool culture. The false positivity or FP rate ( = FP/[FP+TN] or
12specificity) was the proportion of stool samples with no V.
cholerae isolated on culture but showed a positive RDT result. The
false negativity or FN rate ( = FN/[TP+FN] or 12sensitivity) was
the proportion of stool samples with V. cholerae isolated on culture
but showed a negative RDT result.
We performed sub-group analyses by island (Pemba or Unguja),
by previous recent intake versus non-intake of antibiotics and by
receipt of intravenous fluids following previously published studies
showing differences in RDT performance [13]. We defined recent
intake of antibiotics as receipt of any oral or parenteral
antimicrobial for the current illness prior to the collection of a
stool sample. We classified fluid management at the treatment
center as oral rehydration solution (ORS) or intravenous fluids
(IVF) with or without ORS. To assess whether test validity was
related to skill level of the reader and location of the testing, we
compared the performance of the RDT when done in the field
versus in the laboratory on a subset of samples.
Comparison of unpaired samples was done using chi-square
test; comparison of paired samples was done using McNemars test.
Confidence intervals were calculated using exact method. Level of
agreement was calculated using Cohen’s Kappa test for unweight-
ed proportions. Calculations were done using Stata, version 10
(StataCorp, College Station, TX, USA). Performance indicators
were calculated using Excel 2010 (Microsoft, WA, USA).
Results
There were 624 patients who presented to a cholera treatment
camp with acute watery diarrhea and were recruited into the
study: 81 in Unguja and 543 in Pemba. We excluded 2 samples
sent for culture but on which no RDT was done. A total of 622
stool samples were included in the analysis, 79 (13%) from Unguja
and 543 (87%) from Pemba residents (Figure 2).
Performance of the RDT in the field
Of the 622 stool samples, 203 (32.6%) yielded V. cholerae O1. No
V. cholerae O139 was isolated. Using culture results as the gold
standard, we calculated the sensitivity, specificity, PPV, and NPV
of the RDT performed in the field for the diagnosis of cholera
(Table 1). Overall sensitivity was 93.1% (95%CI: 88.7 to 96.2%),
specificity was 49.2% (95%CI: 44.3 to 54.1%), the positive
predictive value (PPV) was 47.0% (95%CI: 42.1 to 52.0%) and the
negative predictive value (NPV) was 93.6% (95%CI: 89.6 to
96.5%). The overall false positivity rate was 50.8% (213/419).
Sub-group analyses of performance of the RDT in the
field
We evaluated the RDT performance by island (Table 1). V.
cholerae was isolated from 46/79 or 58.2% of stool samples from
Unguja compared to a significantly lower proportion of 157/543
or 28.9%, from Pemba (p,0.01). No significant differences in
sensitivity, specificity and NPV of the RDT were observed
between Unguja and Pemba, as well as between each island with
the overall results (all p.0.05). However, we found a significant
difference in PPV between Unguja and Pemba (71.9, 95%CI:
58.5–83.0 versus 42.9, 95%CI: 37.6–48.3; p = 0.02).
We compared the RDT performance by fluid management of
patients: Rehydration treatment at the cholera camp was recorded
for 592/622 (95.2%) participants (Table 2). Only 15.2% (32/210)
of participants who received oral rehydration had a positive stool
Figure 1. Study site.
doi:10.1371/journal.pone.0036930.g001
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Figure 2. Flow of study participants.
doi:10.1371/journal.pone.0036930.g002
Table 1. Performance of the cholera rapid diagnostic test, Pemba and Unguja, Zanzibar.
Sensitivity% (95%CI*)
(TP/(TP+FN))
Specificity% (95%CI*)
(TN/(TN+FP))
PPV% (95%CI*) (TP/
(TP+FP))
NPV% (95%CI*) (TN/
(TN+FN))
No. pos./total (%)
with V. cholera
isolated on stool
culture
Total (n =622) 93.1 (88.7–96.2) (189/203) 49.2 (44.3–54.1) (206/419) 47.0 (42.1–52.0) (189/402) 93.6 (89.6–96.5) (206/220) 203/622 (32.6)
Unguja (n=79) 89.1 (76.4–96.4) (41/46) 51.5 (33.5–69.2) (17/33) 71.9 (58.5–83.0) (41/57) 77.3 (54.6–92.2) (17/22) 46/79 (58.2)
Pemba (n=543) 94.3 (89.4–97.4) (148/157) 49.0 (43.9–54.1) (189/386) 42.9 (37.6–48.3) (148/345) 95.5 (91.5–97.9) (189/198) 157/543 (28.9)
p 0.82 0.87 0.02 0.53 ,0.01
*using exact method.
doi:10.1371/journal.pone.0036930.t001
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culture, compared with 43.2% (165/382) of those who received IV
fluids (p,0.01). There were no statistically significant differences
in sensitivity, specificity and NPV of RDT performance by fluids
received (all p.0.05). However we again found a significant
difference in PPV among those who received oral compared to IV
rehydration (26.8%, 95%CI: 18.9 to 36.0% versus 55.2%, 95%CI:
49.2 to 61.2%; p,0.01). To evaluate whether the provided fluid
treatment biased the field workers’ interpretation of the RDT
results, we compared the false positivity rate by fluid management.
The false positivity rate was 46.1% among those who were orally
rehydrated and 57.1% among those who were intravenously
rehydrated (p = 0.22).
Information on prior antibiotic treatment was recorded for 576/
622 (92.6%) participants. The percentage with a positive stool
culture was 27.6% among those who had received antibiotics and
32.2% among those who had not (p = 0.60). We assessed whether
previous antibiotic treatment affected the RDT performance
(Table 2). Sensitivity, specificity, PPV and NPV did not vary
significantly among recipients and non-recipients of antibiotics.
The false positivity rate was 40.5% among those who had received
antibiotics and 50.7% among those who had not (p = 0.45).
Comparison of the performance of the RDT in the field
versus in the laboratory
We compared the performance of RDT on a subset of 67/79
(84.8%) stool samples from Unguja tested both in the field and in
the laboratory (Table 3). In this subset, 40/67 (59.7%) samples
yielded V. cholerae on culture. There was no statistically significant
difference in the sensitivity, specificity PPV and NPV of the RDT’s
performance (all p.0.05). The false positivity rate of the RDT was
45.4% in the field and 25.9% in the laboratory (Cohen’s kappa
0.8).
Operational characteristics
The test procedure, excluding sample collection, requires 20–
25 minutes. The test kit manual provides clear instructions, and
handling of the test was considered simple by field workers. Field
workers found it easy to distinguish between valid and non-valid
test results, based on the appearance of a control line. However,
very faint positive test lines were interpreted as a positive result,
but could not be confirmed by culture.
Discussion
We found an overall high sensitivity (93.1%) of the current
version of the cholera RDT consistent with previous reports but a
much poorer specificity (49.2%). Earlier studies were performed
using a prototype dipstick – developed by the Institute Pasteur –
and earlier versions of the commercial kit. Studies using the
prototype versions of the RDT reported sensitivities in the range of
93% to 99% and specificities of 67%–97% [12–15]], whereas
more recent reports on earlier versions of the commercial kit
Table 2. Stratified analysis of the performance of cholera dipstick test according to fluid management (oral rehydration or
intravenous fluids) in 592 patients and recent antibiotic intake (yes or no) in 576 patients.
Sensitivity (95%CI)*
(TP/(TP+FN))
Specificity (95%CI)*
(TN/(TN+FP))
PPV (95%CI)* (TP/
(TP+FP))
NPV (95%CI)* (TN/
(TN+FN))
No. pos./total (%)
with V. cholerae
isolated on stool
culture
Fluid management (n =592)
Oral rehydration n=210 93.8 (79.2–99.2) (30/32) 53.9 (46.3–61.4) (96/178) 26.8 (18.9–36.0) (30/112) 98.0 (92.8–99.8) (96/98) 32**/210 (15.2)
Intravenous
rehydrationn=382
92.7 (87.6–96.1) (153/165) 42.9 (36.2–49.7) (93/217) 55.2 (49.2–61.2) (153/277) 88.6 (80.9–94.0) (93/105) 165**/382 (43.2)
p 0.97 0.19 ,0.01 0.62 ,0.01
Recent antibiotic (AB) intake (n=576)
AB received n=58 93.8 (69.7–99.8) (15/16) 59.5 (43.3–74.4) (25/42) 46.9 (29.1–65.3) (15/32) 96.2 (80.4–99.9) (25/26) 16/58 (27.6)
No AB received n=519 92.8 (87.8–96.2) (155/167) 49.3 (43.9–54.7) (173/351) 46.5 (41.1–52.1) (155/333) 93.5 (86.1–94.7) (173/190) 167/518 (32.2)
p 0.98 0.48 0.98 0.86 0.60
*using exact method.
**in 6/203 culture positive cases no rehydration treatment was provided.
doi:10.1371/journal.pone.0036930.t002
Table 3. Comparison of the field and laboratory performance of the cholera dipstick test.
(n = 67)
Sensitivity% (95%CI*)
(TP/TP+FN)
Specificity% (95%CI*)
(TN/TN+FP)
PPV% (95%CI*) (TP/
TP+FP)
NPV% (95%CI*) (TN/
TN+FN)
No. (%) with V. cholera
isolated on stool
culture**
Field 90.0 (76.3–97.2) (36/40) 55.6 (35.3–74.5) (15/27) 75.0 (60.4–86.4) (36/48) 78.9 (54.4–93.9) (15/19) 40 (59.7)
Laboratory 87.5 (73.2–95.8) (35/40) 74.1 (53.7–88.9) (20/27) 83.3 (68.6–93.0) (35/42) 80.0 (59.3–93.2) (20/25) 40 (59.7)
P*** 0.931 0.510 0.740 0.977
*using exact method.
**rapid diagnostic testing was done both in the field and in the laboratory on specimens from the same stool samples.
***using McNemars test.
doi:10.1371/journal.pone.0036930.t003
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showed sensitivities of 92–97% and specificities of 71–76%
[10,11]. These studies not only varied by the RDT version used
but also by the methodology and qualifications of the study
personnel performing the RDT (Table 4). There were also
variations in the test procedure such as addition or non-addition of
a buffer solution to the sample. In some studies, a 4-hour
incubation step in alkaline peptone water was added. Overall, the
prototype and precursor commercial kits performed better than
the current version tested.
The poor specificity of the current version of the commercial kit
was associated with an overall false positive rate of 50.8%. The
RDT’s false positivity rate when the RDT was read in the field was
44% versus 26% when done by laboratory technicians; possibly
faint test lines on the dipsticks were over-read by field workers as
positive. We hypothesized whether patient characteristics (fluid
management or receipt of antibiotics) biased the field workers’
interpretation of the RDT results. However, we found no
significant differences in false positivity in these sub-group
analyses. More likely the fieldworkers over-interpreted faint test
lines which could be recognized in daylight but not in the indoor
laboratory setting.
Previously, Kalluri et al. assessed the impact of the reader’s
qualification on the performance of the prototype test [12].
Laboratory technicians with several years of working experience as
well as field workers with at least a college degree but no
laboratory experience were asked to perform the test on 304 stool
samples. The reported RDT sensitivities of 94% and 93% when
done by laboratory technicians and field workers, respectively,
were similar, but RDT specificity was higher when performed by
the technicians (76% versus 67%) [12]. Harris et al. report a
sensitivity of 97% and a specificity of 71–76%, when staff with
graduate-level laboratory training performed the test in Guinea
Bissau [10]. Mukherjee et al. reported a similar sensitivity and
specificity (92% and 73%, respectively) when the test was done by
graduate-level staff during a surveillance study at a hospital in
Kolkata [11].
In contrast to Wang et al., we did not find a higher sensitivity of
the RDT when testing stool samples from patients receiving IVF
compared to samples from patients who did not receive IVF [13].
However, we noted that the PPV in this study varied according to
the proportion of culture-positive specimens. It has been argued
that PPV is the most important measure of a clinical diagnostic
method since it represents the proportion of patients with positive
test results that are correctly diagnosed [18]. The PPV is not
intrinsic to the test; it is affected by prevalence of the disease. For
example, the PPV was 55% for samples from patients given IVF
(43% of whom had V. cholerae isolated) while it was 27% for
samples from patients managed with ORS (15% of whom had V.
cholerae isolated). The PPV was 71.9% for the Unguja sub-sample
with 58% cholera confirmation while for the Pemba sub-sample it
was 43% with 29% cholera confirmation. In outbreak settings,
when a large proportion of patients presenting with acute watery
diarrhea have cholera, a positive RDT result would have a good
predictive value. In other situations (e.g. areas with seasonal
cholera but also high rates of diarrheal diseases from other
pathogens), the RDT may be less useful.
Our study has several limitations. Firstly, a large sample from
622 study participants was available for the overall evaluation, but
only 67 stool samples were used for sub-analyses. Secondly, while
confirmation of V. cholerae isolates was performed at a reference
laboratory, culture-negative stool samples were not validated
further. In particular, we did not perform PCR testing on our
RDT-positive, culture-negative samples. Bhuiyan, et al. [14]
analyzed five stool samples collected in Bangladesh by multiplex
PCR that were O1 dipstick positive but culture-negative and
found that all five were negative by PCR, indicating that the five
dipstick-positive results were false positives. This is reassuring but
does not entirely exclude the possibility of false negativity by stool
culture. Thirdly, Alam et al. pointed out that the dipstick may
detect non-culturable forms of V. cholerae that have transformed
into a coccoid form due to unfavorable intra-host conditions, such
as antibiotic treatment prior to testing [7]. We tried to assess the
influence antibiotic treatment prior to sample collection may have
had on our results but found no significant difference (p.0.05) in
the false positive rates among participants who had taken
antibiotics prior to sample collection and those who had not.
However, further research is needed to rule out the possibility that
the RDT may detect V. cholerae antigen in some specimens which
are culture negative.
Conclusion
We found that field workers in this study who had basic general
education but were not familiar with laboratory work experienced
difficulties in interpreting the RDT performed in the cholera
camps. If the RDT is to be deployed more widely, more extensive
and repeated training may be required to improve the current
RDT’s specificity. The test cannot replace stool culture and due to
the high number of false positive results observed is not suitable to
trigger an outbreak response in a resource poor setting. However
the test may be potentially used as a screening tool. During cholera
outbreaks, especially when several samples test positive, the test
has an enhanced predictive value. Further research is needed to
evaluate the accuracy of the RDT with specimens which have
been incubated in APW for 4 to 6 hours prior to testing in the
RDT since this procedure should dilute out the materials in stool
samples which are causing the false positive results while
amplifying the antigen signal from the V. cholerae.
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